Cancer diagnosis and treatment by PRMT5 inhibitors

By measuring the pRb and total E2F1 expression levels in cancer cells, selecting cancer patients suitable for treatment with PRMT5 inhibitors solves the problem of difficult to identify suitable patients in the prior art, and achieving the goal of personalized treatment and improving the therapeutic effect.

CN118891379APending Publication Date: 2024-11-01ARGONAUT THERAPEUTICS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380028262.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-15
Filing Date
2023-03-14
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The prior art is difficult to effectively identify and select the most suitable treatment methods for PRMT5 inhibitors for patients with a particular type of cancer, and personalized medicine requires a method to distinguish patients who may respond well to drugs to avoid unnecessary treatment and toxic side effects.

Method used

By measuring the expression levels of pRb and total E2F1 in cancer cells and comparing them to the reference value, if pRb expression is reduced or total E2F1 expression is increased, patients were selected for PRMT5 inhibitor treatment. Meanwhile, kits are provided for determining the levels of these biomarkers and for treatment with PRMT5 inhibitors.

Benefits of technology

Personalized treatment options for cancer patients are achieved, the effectiveness and safety of treatment are improved, the appropriate drug response to specific types of cancer patients is ensured, and the risk of inappropriate treatment is reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005046797070000291
    Figure BDA0005046797070000291
  • Figure BDA0005046797070000301
    Figure BDA0005046797070000301
  • Figure BDA0005046797070000311
    Figure BDA0005046797070000311
Patent Text Reader

Abstract

The present invention relates to methods of patient selection and methods of treating cancer with protein arginine methyltransferase 5 (PRMT5) inhibitors. The expression level of retinoblastoma tumor suppressor protein (pRb) and / or total E2F1 protein in a cancer cell-containing biological sample from a patient is used to determine whether the patient should be treated with a PRMT5 inhibitor.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of cancer, and in particular to a method for selecting a patient and a method for treating cancer with a PRMT5 inhibitor. The present invention also provides a kit for the method of the present invention. Background Art

[0002] The retinoblastoma protein (pRb)-E2F pathway is a key control point in the cell cycle. It is often dysregulated in tumor cells, and dysregulation of this pathway is widely considered a "signature" of cancer. Traditionally, the pRb tumor suppressor protein is a negative regulator of the E2F transcription factor, which acts as a transcriptional hub through which pRb affects cell cycle progression.

[0003] PRMT5 has been identified as a therapeutic target for treating cancer. In fact, many patent publications disclose PRMT5 inhibitors and their use in treating cancer.

[0004] However, cancer is a heterogeneous disease, and there are subpopulations of cancer within patients with a particular type of cancer, such as breast or lung cancer. It is generally accepted that no single drug works to treat all people with a particular type of cancer, but the advent of personalized medicine, which can identify those patients most likely to respond well to a particular type of drug, such as by using a diagnostic test that characterizes a genetic mutation for response, means that people who are likely to respond to drugs can be identified and treated, and people who do not respond to treatment with drugs that may not work but may cause toxic side effects can be excluded. Thus, these likely non-responders can avoid inappropriate treatment and be treated in other ways.

[0005] Particularly in the field of oncology, there is a continuing need for methods to identify patients who will respond, or are most likely to respond, to a particular type of treatment.

[0006] E2F is a family of transcription factors involved in multiple cell fates, including proliferation, apoptosis, and differentiation (Stevens and La Thangue; 2003; Frolov and Dyson 2004, Polager and Ginsberg 2008; van den Heuvel and Dyson 2008). E2F proteins have the ability to regulate a variety of target genes (Frolov and Dyson 2004; van den Heuvel and Dyson 2008). The first family member identified, E2F-1, physically interacts with the retinoblastoma tumor suppressor protein pRb, which negatively regulates E2F-1 activity (Bandara and La Thangue 1991; Zamanian and La Thangue 1992; Weinberg 1995; Stevens and La Thangue 2003). While it is well established that E2F-1 can promote proliferation, it is also clear that E2F-1 can promote apoptosis (van den Heuvel and Dyson 2008, Polager and Ginsberg 2008). In Rb- / - mice, increased levels of apoptosis in certain tissues reflect dysregulated E2F-1 activity (Tsai et al., 1998; Iaquinta and Lees 2007). In addition, the incidence of tumors is increased in E2F-1- / - mice (Field et al., 1996), suggesting that E2F-1 plays a tumor suppressor role in some tissues, which may reflect its ability to induce apoptosis. However, the mechanisms that influence the various cellular outcomes attributed to E2F-1 activity, especially its apoptotic activity, and the cellular context dependence of these events remain elusive. The purpose of the present invention is to identify such mechanisms.

[0007] E2F-1 is regulated not only during cell cycle progression (Stevens and La Thangue, 2003, van den Heuvel and Dyson 2008), but also under conditions of DNA damage (Pediconi et al., 2003; Stevens et al., 2003; Stevens and La Thangue, 2003). In cells with DNA damage, E2F-1 is induced in a manner that follows kinetics similar to p53 (Pediconi et al., 2003; Stevens and La Thangue, 2003), which coincides with the activation of a diverse set of E2F target genes (Ren et al., 2002). DNA damage activates a signaling pathway involving protein phosphokinases such as ATM / ATR and Chk1 / Chk2, which in turn phosphorylate effector proteins that mediate the outcomes of the DNA damage response (Jackson and Bartek, 2009). Both families of DNA damage response kinases phosphorylate E2F-1, which helps regulate E2F-1 in cells with DNA damage (Stevens et al. 2003; Stevens and La Thangue 2003). In addition, E2F-1 promotes apoptosis under conditions of DNA damage and may provide an important pathway for apoptosis to be activated in tumor cells with impaired p53 activity (Stevens and La Thangue 2003).

[0008] The retinoblastoma tumor suppressor protein (pRb) is a key regulator of the G1 to S phase transition in the cell cycle, a process that is essential for the proper control of cell proliferation (Dick and Rubin, 2013). Loss of pRb / Rb1 is common in all cancer types and is strongly associated with poor overall survival (Knudsen et al., 2020 and Ertel et al., 2010). Loss of Rb in cancer can occur through the loss of one or both copies of the gene, mutations that result in a nonfunctional protein, or through methylation of the Rb gene promoter (Hanahan and Weinberg, 2000). In addition to mutations in the RB1 gene itself, abnormalities in the upstream RB pathway can occur in a high proportion of human cancers, such as inactivation of CDK inhibitors and activation of cell cycle proteins and CDKs are frequent events (Hanahan and Weinberg, 2000).

[0009] PRMT5 is a member of the protein arginine methyltransferase (PRMT) family. PRMT5 is a type II methyltransferase that catalyzes the symmetric dimethylation of its substrate proteins (Bedford and Clarke et al., 2009). Arginine methylation is known to play a role in a variety of cellular processes. In recent years, an increasing number of reports have highlighted the potential role of PRMT5 as a driver of tumorigenesis (Jarrold and Davis, 2019, Kim and Ronai, 2020). PRMT5 has been shown to promote tumorigenesis in a wide range of cancers, including hematological malignancies, colon cancer, breast cancer, prostate cancer, lung cancer, liver cancer, bone cancer, skin cancer, ovarian cancer, gastric cancer, brain cancer, and pancreatic cancer (Shailesh et al., 2018).

[0010] E2F-1 has been shown to be a target of methylation by the protein arginine methyltransferase PRMT5. Methylation of E2F1 by PRMT5 promotes cell growth by increasing transcription of cell cycle-related E2F1 target genes (Cho et al., 2012 and Zheng et al., 2013). In addition, a subset of genes controlled by E2F1 and PRMT5 has been identified that can affect the viability, migration, invasion, and adhesion of cancer cells (Barczak et al., 2020). High levels of expression of E2F1 and PRMT5 are commonly found in many cancers and have been found to be associated with poor prognosis (Barczak et al., 2020).

[0011] There is a need in the art for methods of selecting patients who are most likely to respond favorably to PRMT5 inhibitors for cancer treatment. The present invention satisfies this need. Summary of the invention

[0012] According to a first aspect of the present invention, there is provided a method for selecting a treatment for a cancer patient, comprising:

[0013] (i) determining the expression level of the biomarkers (a) pRb and / or (b) total E2F1 in a biological sample comprising cancer cells from a patient;

[0014] (ii) comparing the expression level in (i) with a reference value for each biomarker,

[0015] (iii) wherein said patient is selected for treatment with a PRMT5 inhibitor if said patient's cancer cells show decreased pRb expression and / or increased total E2F1 expression compared to a reference value.

[0016] The expression level of pRb can be determined by quantifying the amount of pRb protein or the amount of RB1 transcript in a sample. The expression level of total E2F1 can be determined by quantifying the amount of total E2F1 protein or the amount of E2F1 transcript in a sample.

[0017] Total E2F-1 refers to the sum of all types of E2F-1, not just one form of E2F-1, such as methylated E2-F1.

[0018] According to a second aspect of the invention, a method for selecting treatment for a cancer patient is provided, comprising determining whether the PRB1 gene in the cancer cells contains one or more mutations that result in reduced pRb expression (including zero expression), wherein if the cancer cells contain one or more mutations in the RB1 gene that result in reduced pRb expression, the patient is selected for treatment with a PRMT5 inhibitor.

[0019] According to a third aspect of the present invention, there is provided a kit for use in the method of the first aspect of the present invention, the kit comprising one or more reagents capable of determining the expression level of pRb and / or total E2F1. Suitably, the kit comprises an antibody or antigen binding portion thereof that specifically binds to E2F-1 protein; and / or an antibody or antigen binding portion thereof that specifically binds to pRb protein; and / or a nucleic acid oligonucleotide that can specifically bind to RB1 transcript; and / or a nucleic acid oligonucleotide that can specifically bind to E2F1 transcript.

[0020] According to a fourth aspect of the present invention, there is provided a PRMT5 inhibitor for use in treating a patient identified according to the first aspect of the present invention.

[0021] Specifically, according to a variant of the fourth aspect of the present invention, there is provided a PRMT5 inhibitor for use in treating cancer, wherein cells of the cancer express higher than normal levels of total E2F1 protein and / or reduced levels of pRb protein compared to normal.

[0022] According to a fifth aspect of the present invention, a PRMT5 inhibitor is provided for use in treating pRb-deficient cancer or for treating cancer in which the level of pRb biomarker expressed by cells is reduced compared to normal.

[0023] Suitably, a pRb-deficient cancer is a cancer comprising cancer cells comprising one or more mutations in the RB1 gene, said mutations resulting in reduced expression of pRb, including zero expression, in the cancer cells.

[0024] Any agent capable of inhibiting PRMT5 may be used in the fourth or fifth aspect of the present invention. Suitably, the PRMT5 inhibitor is a small molecule compound, an antisense oligonucleotide, an RNAi molecule or an antibody or a binding fragment thereof.

[0025] According to a sixth aspect of the present invention, there is provided a computer-implemented method for assisting in selecting a treatment for a cancer patient, the method comprising the following steps:

[0026] (i) receiving a level value of the biomarker (a) pRb and / or (b) total E2F1 in a biological sample containing cancer cells from a patient;

[0027] (ii) comparing the level in (i) with a reference value for each biomarker,

[0028] (iii) wherein the patient is selected for treatment with a PRMT5 inhibitor if the patient's cancer cells show decreased pRb levels and / or increased total E2F1 levels compared to reference values.

[0029] Suitably, the level is an expression level.

[0030] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the invention belongs. Although methods and materials similar or equivalent to the methods and materials described herein may be used in the practice or detection of the present invention, suitable methods and materials are described below. In the event of a conflict, this specification shall prevail, including definitions. In addition, materials, methods and examples are illustrative only, not restrictive.

[0031] Other features and advantages of the present invention will become apparent from the following: DETAILED DESCRIPTION

[0032] The disclosed methods may be more readily understood by reference to the following detailed description, which forms a part of the present disclosure. It should be understood that the disclosed methods are not limited to the specific methods described and / or illustrated herein, and that the terminology used herein is only used for the purpose of describing specific embodiments by way of example and is not intended to limit the claimed methods.

[0033] Unless otherwise indicated, the methods of the present disclosure will employ conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the technical scope of the art. Exemplary techniques are fully explained in the literature, for example, "Molecular Cloning: A Laboratory Manual" Second Edition (Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989); "Current Protocols in Molecular Biology" (FM Ausubel et al., eds., Current Protocols of Molecular Biology, John Wiley and Sons, 1987); and "PCR: The Polymerase Chain Reaction" (Mullis et al., eds., Boston, 1994).

[0034] In describing the present invention, the following terminology will be used and is intended to be defined as described below.

[0035] It should be understood that, for the sake of clarity, certain features of the disclosed method described herein in the context of separate embodiments may also be provided in combination in a single embodiment. Conversely, for the sake of brevity, the various features of the disclosed method described in the context of a single embodiment may also be provided individually or in any sub-combination.

[0036] The articles "a," "an," and "the" are used herein to refer to one or more (ie, to at least one) of the grammatical object of the article.

[0037] The use of alternatives (eg, "or") should be understood to mean one, two, or any combination of the alternatives.

[0038] The term "and / or" should be understood to mean one or both of the two alternatives.

[0039] As used herein, unless otherwise specified, it should be understood that the term "about" is used synonymously with the term "approximately". Illustratively, unless otherwise specified, the term "about" when used in conjunction with a stated value or range means slightly larger or slightly smaller than the stated value or range, within ±15% of the stated value, ±10% of the stated value, ±5% of the stated value, or conveniently ±2% of the stated value. Therefore, these values ​​are included in the scope of the claims reciting the term "about" or "approximately".

[0040] As used herein, "cancer sample" or "cancer cell-containing sample" refers to any biological sample obtained from a cancer patient that contains one or more cancer cells or one or more cancer-derived RNAs or proteins. For example, a tissue sample obtained from a cancer tissue of a cancer patient is a useful cancer sample in the present invention. The tissue sample can be a formalin-fixed, paraffin-embedded (FFPE) sample, or a fresh frozen sample, and preferably contains primarily cancer cells.

[0041] As used herein, the term "effective amount" or "therapeutically effective amount" refers to the amount of a pharmaceutical agent that confers a therapeutic effect on the treated subject at a reasonable benefit / risk ratio applicable to any medical treatment. The therapeutic effect can be objective (i.e., measurable by some test or marker) or subjective (i.e., the subject gives an indication or feels the effect). Specifically, an "effective amount" refers to an amount of a therapeutic drug that effectively treats, ameliorates or prevents a desired disease or condition, or exhibits a detectable therapeutic or preventive effect, such as by improving symptoms associated with the disease, preventing or delaying the onset of the disease, and / or reducing the severity or frequency of disease symptoms.

[0042] The effective amount is usually administered with a dosage regimen including multiple unit doses. For any specific therapeutic drug, the effective amount (and / or the appropriate unit dose in the effective dosage regimen) can vary, for example, depending on the route of administration, depending on the combination with other drugs. In addition, the specific effective amount (and / or unit dose) of any particular patient may depend on a variety of factors, including the condition being treated; the severity of the condition; the activity of the specific drug used; the specific ingredients used; the age, weight, general health and diet of the patient; the time of administration, the route of administration; the duration of treatment; and similar factors well known in the medical field. The therapeutically effective amount is usually a drug dosage approved by a national health agency (such as the U.S. Food and Drug Administration [FDA] or the European Medicines Agency [EMA]), which will be identified from controlled human clinical trials.

[0043] The term "inhibitor" as used herein refers to an entity / agent whose presence in a system in which an activity of interest is observed is associated with a reduction in the level and / or properties of the activity, compared to the level and / or properties of the activity observed under otherwise comparable conditions when the inhibitor is not present. In some embodiments, the inhibitor interacts directly with the target of the activity of interest. In some embodiments, the inhibitor affects the amount / level of the target of interest; optionally or additionally, in some embodiments, the inhibitor affects the activity of the target of interest without affecting the level of the target. In some embodiments, the inhibitor affects the level and activity of the target entity of interest, such that the observed differences in activity cannot be fully explained or equivalent to the observed differences in levels. The inhibitor can be any agent, such as a small molecule compound, a nucleic acid, an antibody, etc. The target can be a protein or a precursor thereof, or a nucleic acid encoding the protein / precursor, such as genomic DNA or mRNA.

[0044] The term "oligonucleotide" refers to a relatively short polynucleotide, including but not limited to single-stranded deoxyribonucleotides, single-stranded or double-stranded ribonucleotides, RNA / DNA hybrids and double-stranded DNA. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are usually synthesized by chemical methods, for example using a commercially available automatic oligonucleotide synthesizer. However, oligonucleotides can be prepared by a variety of other methods, including in vitro recombinant DNA-mediated technology and by expressing DNA in cells and organisms.

[0045] The term "polynucleotide" when used in the singular or plural generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.

[0046] As used herein, the term "primer" refers to a molecule, typically a single-stranded oligonucleotide, that can be used to generate an amplification product (amplicon) in a PCR reaction. Primers are sometimes referred to as PCR primers.

[0047] The term "probe" as used herein refers to a molecule, typically a single-stranded oligonucleotide, that can be used to detect a complementary target nucleic acid product by hybridizing therewith due to sequence complementarity. The probe can be labeled, such as with a fluorescent marker or other label to facilitate detection. The probe is sometimes referred to as a hybridization primer.

[0048] The term "RNA transcript" as used herein refers to the RNA transcription product of a gene, including, for example, mRNA, unspliced ​​RNA, splice variant mRNA, microRNA, and fragmented RNA.

[0049] As used herein, "selective hybridization" refers to being able to hybridize only to a unique complementary single region of a target in a sample, such as under conditions that allow selective hybridization to a target nucleic acid. In this way, each primer or probe can hybridize to only one target sequence, thereby avoiding off-target binding.

[0050] Selective hybridization typically occurs when the two nucleic acid sequences are substantially complementary (at least about 75% complementary over a stretch of at least 14 to 25 nucleotides, preferably at least about 85% complementary, more preferably at least about 90% complementary). Thus, it is expected that some mismatch can be tolerated.

[0051] Those skilled in the art will be able to employ appropriate conditions of desired stringency for selective hybridization, taking into account factors such as oligonucleotide length and base composition, temperature, and the like.

[0052] For oligonucleotides of about 17-35 bases, suitable selective hybridization conditions include hybridization at 42°C for 1 h in 6xSSC and washing in 6xSSC at a series of increasing temperatures from 42°C to 65°C. For example, 6xSSC can be used for washing at 42°C for 30 min, followed by 6xSSC for washing at 50°C for 45 min, and then 2xSSC for washing at 65°C for 45 min. When performing PCR, the reaction conditions for selective hybridization can include reacting the target nucleic acid and probe / primer for 5-10 min at about 50-60°C in a suitable buffer.

[0053] The stringency of washing can be changed by changing the temperature, pH, ionic strength, divalent cation concentration, volume and duration of washing. For example, the stringency of hybridization can be changed by hybridizing at different temperatures below the melting temperature of the primer or probe. For oligonucleotide probes between 14 and 70 nucleotides in length, the melting temperature (Tm) in degrees Celsius can be calculated using the following formula: Tm=81.5+16.6(log[Na+])+0.41(fragment G+C)-(600 / N), where N is the length of the oligonucleotide.

[0054] Other suitable conditions and protocols are described in Molecular Cloning: A Laboratory Manual; 4th ed., Green & Sambrook (2012) Cold Spring Harbor Laboratory Press NY; and Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley & Sons (2003).

[0055] As used herein, "subject" includes vertebrates, mammals, livestock, or preferably humans.

[0056] As used herein, "subject," "individual," or "patient" includes any animal that exhibits symptoms of a condition that can be detected or identified using the compositions contemplated herein. Suitable subjects include laboratory animals (such as mice, rats, rabbits, or guinea pigs), farm animals (such as horses, cattle, sheep, pigs), and livestock or pets (such as cats or dogs). In specific embodiments, the subject is a mammal. In certain embodiments, the subject is a non-human primate, and in specific embodiments, the subject is a human.

[0057] An individual "suffering from" a disease, disorder, and / or condition has been diagnosed with and / or exhibits one or more symptoms of the disease, disorder, and / or condition. When referred to herein, an individual suffering from a disease (e.g., cancer) is also an individual who has the disease (e.g., cancer) or is in need of treatment for the disease (e.g., cancer).

[0058] The term "treatment" (also referred to as "treat" or "treating") as used herein refers to any administration of a substance (e.g., a PRMT5 inhibitor) that partially or completely alleviates, improves, alleviates, inhibits, delays the onset of, reduces the severity of, and / or reduces the frequency, incidence, or severity of one or more specific diseases, disorders, and / or conditions (e.g., cancer). This treatment can be the treatment of a subject who does not show signs of a related disease, disorder, and / or condition, and / or the treatment of a subject who only shows early signs of a disease, disorder, and / or condition. Optionally or additionally, this treatment can be the treatment of a subject who shows confirmed signs of one or more related diseases, disorders, and / or conditions. In some embodiments, a subject who has been diagnosed with a related disease, disorder, and / or condition can be treated. The treatment can be part of a "treatment method," which can include diagnosis or selection of a patient / individual and therapeutic intervention. The selection of a patient can include testing the suitability of the patient for therapeutic intervention, which can include testing to determine whether the patient's cancer has a related defect in a protein or encoding nucleic acid. In the context of the present invention, this can be a test to see if the cancer comprises cells that express higher levels of total E2F1 than normal cells; and / or express lower levels of pRb than normal cells; and / or comprises one or more mutations in the PRB1 gene that result in reduced expression of pRb in the cancer cells, including zero expression. Suitably, this test is performed in vitro on a biological sample comprising cancer cells from a subject having or suspected of having cancer.

[0059] Diagnostic Methods

[0060] The present invention arises from the recognition that the cancer cell targeting effect of PRMT5 inhibitors is significantly increased in cancers expressing higher than normal levels of E2F1, particularly those with higher than normal levels of total E2F1; in addition, the cancer cell targeting effect of PRMT5 inhibitors is significantly increased in cancers expressing pRb below normal levels (including no expression). Therefore, cancer cells with a phenotype of enhanced total EF21 expression and / or reduced pRb expression are most suitable for treatment with PRMT5 inhibitors. Therefore, this discovery provides the opportunity to select patients who are most suitable for effective anti-cancer treatment with PRMT5 inhibitors.

[0061] Therefore, according to a first aspect of the present invention, there is provided a method for selecting a treatment for a cancer patient, comprising:

[0062] (i) determining the expression level of the biomarkers (a) pRb and / or (b) total E2F1 in a biological sample comprising cancer cells from a patient;

[0063] (ii) comparing the expression level in (i) with a reference value for each biomarker,

[0064] (iii) wherein said patient is selected for treatment with a PRMT5 inhibitor if said patient's cancer cells show decreased pRb expression and / or increased total E2F1 expression compared to a reference value.

[0065] The expression level of a biomarker such as pRb can be determined by quantifying the amount of protein in a sample or the amount of a transcript encoding the protein. In humans, the retinoblastoma protein (protein name abbreviated as pRb; gene name abbreviated as Rb, RB or RB1) is encoded by the RB1 gene located at 13q14.1-q14.2 of chromosome 13. NCBI discloses the reference sequence of the protein, which is NP_000312. NCBI discloses the reference sequence of the RB1 gene, which is CCDS31973.1. The reference sequence can also be obtained from G! Ensembl with ENSG00000139687 and from UniProtKB with reference P06400.

[0066] The RB1 nucleotide sequence is disclosed in SEQ ID NO:1.

[0067] The translated protein (pRb) sequence is disclosed in SEQ ID NO:2.

[0068] In humans, E2F transcription factor 1 (E2F1) is located on chromosome 20. The gene is mapped at GRCh37 coordinates 32,263,283-32,274,191.

[0069] NCBI has published a reference sequence for the protein, the reference sequence is NP_005216-1. NCBI has published a reference sequence for the E2F1 gene, the reference sequence is CCDS13224.1. The reference sequence can also be obtained from G! Ensembl as ENSG00000101412.

[0070] The E2F1 nucleotide sequence is disclosed in SEQ ID NO:3.

[0071] The translated protein sequence is disclosed in SEQ ID NO:4.

[0072] These sequences can be used to design nucleic acid probes or primers capable of binding to the transcripts, or antibodies suitable for use with the proteins of the invention disclosed herein.

[0073] The expression level of the biomarker in the cancer cell sample (e.g., the amount of protein or transcript) must be compared to assess whether the level is rising, falling or remaining unchanged. This comparison can be performed with a reference value indicating a wild-type or normal biomarker level. This reference level can be determined by analyzing a biological sample containing wild-type cells in parallel with a biological sample containing cancer cells from a patient and comparing the expression level of the biomarker in each sample. Suitably, the two samples include approximately the same number and type of cells to ensure comparability. Therefore, if the cancer cell sample is a breast tissue sample, the comparison sample can be a matching non-cancerous breast tissue sample from the same patient or a different subject. More suitably, the typical expression level of the biomarker in the matching non-cancerous tissue will have been pre-determined from the analysis of a large number of samples from non-cancerous tissue (e.g., from a healthy subject). In one method, the average value of this wild-type level can be used as a reference value. In another method, a threshold value (e.g., 5 percentile value or 95 percentile value) can be obtained from the wild-type level. Thus, for example, when attempting to detect an increase in the expression level of a biomarker in a test sample, an indicative value representing a value representing 95% of the highest value may be used as a reference value. Alternatively, when attempting to detect a decrease in the expression level of a biomarker in a test sample, an indicative value representing a value representing 5% of the highest value may be used as a reference value. It should be understood that the 5% and 95% values ​​used herein are merely illustrative. The actual reference value for each biomarker may be established from appropriately controlled clinical studies.

[0074] Mutations in the RB1 gene can result in reduced expression of pRb relative to normal levels (Derenzini et al., 2008, Benedict et al., 1999, Bhateja et al., 2019, Lacombe et al., 2021, Xing et al., 1999). Therefore, by detecting one or more mutations in the pRB gene that result in reduced expression, it can be determined that the patient's cancer is a cancer with reduced pRb expression levels.

[0075] Therefore, according to the second aspect of the present invention, a method for selecting treatment for a cancer patient is provided, comprising determining whether the RB1 gene in the cancer cell contains one or more mutations that result in reduced pRb expression (including zero expression), wherein if the cancer cell contains one or more mutations in the RB1 gene, and the mutations result in reduced pRb expression (including zero expression) in the cancer cell, the patient is selected for treatment with a PRMT5 inhibitor.

[0076] Suitably, the analysis is performed in vitro (including ex vivo) on a sample of cancer cells previously isolated from a patient.

[0077] Suitably, the mutation is selected from one of E137X, R251X, R255X, R320X, R358X, R445X, R455X, R467X, R552X, R556X, R579X, R787X, R661W, C712R.

[0078] The mutation identifier follows the established practice of identifying the amino acid in the wild-type protein, the position of the amino acid, and then the amino acid that is substituted in the mutant form, so C712R identifies an arginine (R) substitution for a cysteine ​​(C) at position 712. X indicates a substitution of any amino acid.

[0079] Those skilled in the art can easily design probes or primers that can specifically identify the presence of nucleic acids encoding the above-mentioned amino acid substitution mutations.

[0080] The presence of a mutation in the RB1 gene can be determined using a number of established techniques, including nucleic acid sequencing; or using amplification techniques (such as polymerase chain reaction), using one or more primers that produce extension products only when a specific base mutation is present (such as allele-specific amplification); or using one or more probes that can selectively distinguish between nucleic acids with or without one or more mutations (such as allele-specific hybridization). Preferably, the presence or absence of a mutation in the RB1 gene is determined by nucleic acid sequencing.

[0081] sample

[0082] The level of a biomarker (eg, E2F1 or pRb) or the presence of one or more mutations in the RB1 gene can be determined from any suitable sample containing cancer cells (cancer sample) from a patient.

[0083] The skilled person will appreciate that there are many suitable examples of cancer cell samples that can be used. Suitable biological samples can be tissue samples, such as samples from biopsy or surgical resection, or biological fluid samples containing tumor cells, such as blood, plasma, serum, sputum, saliva, pleural effusion, ascites, urine, etc. Suitably, the sample is fresh, frozen (e.g., fresh frozen), or paraffin embedded and fixed (e.g., formalin fixed).

[0084] In a specific embodiment, the cancer sample has been previously isolated from the patient, optionally as a solid or liquid biopsy sample or during surgery.

[0085] In one embodiment, said sample separation is part of a diagnostic method.

[0086] Suitably, the cancer sample is isolated during surgical tumor resection, or from a solid or liquid biopsy, such as a fine needle aspiration biopsy, a core needle biopsy, or a liquid biopsy (eg, a blood or ascites sample).

[0087] In certain embodiments, the cancer sample is fresh, frozen, or paraffin-embedded and fixed.

[0088] Determine protein levels

[0089] The expression level of each biomarker can be determined based on the amount of protein present in the sample.

[0090] In one embodiment of the invention, biomarker expression levels can be determined at the protein level. These methods are well known in the art, including, for example, any immunohistochemistry (IHC)-based, antibody-based (including autoantibodies to proteins), mass spectrometry-based, and image-based (including using labeled ligands) methods, which are known in the art and are considered to be applicable to protein detection.

[0091] Normalization can then be performed against a reference protein to facilitate quantification of the biomarker. The normalized value can then be compared to a wild-type / normal cell biomarker expression level or threshold to see if the cancer expresses more or less of the measured biomarker than wild-type, and / or to classify the cancer as one that may or may not respond favorably to a PRMT5 inhibitor.

[0092] In a specific embodiment, the expression level of each biomarker (eg, E2F1 or pRb) is determined based on the amount of biomarker protein detected.

[0093] In one embodiment, the detection is performed by an immunoassay using one or more antibodies specific for one or more epitopes of the biomarker protein in the cell sample of interest.Any biological material can be used for the detection / quantification of the biomarker protein.

[0094] Biomarker proteins can be detected in any suitable manner, but are typically detected by contacting a sample from a patient (i.e., a sample containing cancer cells) with an antibody that binds to the biomarker protein and then detecting the presence or absence of the reaction product. For example, by using labeled antibodies for cell surface markers and then performing fluorescence activated cell sorting (FACS). These antibodies are preferably labeled to allow them to be easily detected after binding to the gene product. Detection methods suitable for implementing the present invention include, but are not limited to, immunohistochemistry of samples or tissues containing cells, enzyme-linked immunosorbent assays (ELISAs), mass spectrometry, and immuno-PCR of antibody sandwich assays of tissues or blood samples containing cells.

[0095] The antibodies useful herein may be monoclonal antibodies, polyclonal antibodies, chimeric antibodies or fragments of the foregoing antibodies. Suitably, the antibody is a monoclonal antibody. Suitably, the step of detecting the reaction product may be performed using any suitable immunoassay.

[0096] Antibodies to known proteins, including marker antibodies, are generally commercially available. However, antibodies that can specifically bind to one of the biomarkers (e.g., E2F1 or pRb) can be prepared using established protocols. General procedures for preparing antibodies are described in Harlow, E. and Lane, D., Using Antibodies: A Laboratory Manual, Cold Spring Harbor Press, New York, 1999; Zola, H., Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc., Boca Raton, Florida, 1984; and Coligan, CURRENT PROTOCOLS IN IMMUNOLOGY, Wiley / Greene, NY, 1991, which are incorporated herein by reference.

[0097] In addition to full-size / intact antibodies (which can be any immunoglobulin type, including IgG, IgM, IgE, IgA, IgD, and any subclass thereof), fragments thereof (e.g., Fab or F(ab')2) or engineered variants thereof (e.g., sFv) can also be used. These portions are collectively referred to as antigen binding portions. The antigen binding portion is optionally conjugated to a detectable label.

[0098] The technology of detecting antibody binding by using a detectable label is well known in the art. For example, antibody binding can be detected by using a chemical reagent that produces a detectable signal, and the detectable signal corresponds to the level of antibody binding, and therefore corresponds to the level of biomarker protein expression. In some embodiments, the detection antibody is coupled to an enzyme, particularly an enzyme that catalyzes the deposition of a chromogen at the antigen-antibody binding site. Suitable enzymes include, but are not limited to, horseradish peroxidase (HRP) and alkaline phosphatase (AP). Commercial antibody detection systems can also be used to implement the present invention. As used herein, antibody binding also encompasses the binding of an antigen-binding moiety.

[0099] Although antibody / antigen binding moieties are described herein for use in the present invention due to their extensive characterization, any other suitable agent (e.g., a peptide, aptamer, or small organic molecule) that specifically binds a biomarker is optionally used in place of an antibody. For example, an aptamer that specifically binds a selected biomarker can be used. Aptamers are nucleic acid-based molecules that bind to a specific ligand. Methods for preparing aptamers with specific binding specificities are known in the art.

[0100] As described elsewhere, the sample from the subject is typically a solid tissue sample, such as a biopsy as described above, but can also be a cancer cell containing biological fluid, such as a blood or serum sample. The sample can be in the form of a tissue sample from the patient, wherein the sample is suitable for immunohistochemistry in various forms, such as paraffin-embedded tissue, frozen sections of tissue, and freshly isolated tissue. Immunodetection methods are based on antibodies, but there are many other techniques that can be used to highly sensitively determine the binding of antibodies in tissues. Those skilled in the art are familiar with various immunohistochemical strategies.

[0101] The immunoassays performed according to the present invention can be homogeneous assays or heterogeneous assays. In homogeneous assays, the immune response generally involves specific antibodies (e.g., anti-biomarker protein antibodies), labeled analytes and target samples. When the antibody is combined with the labeled analyte, the signal produced by the label is modified directly or indirectly. The detection of the immune response and its degree is all carried out in a homogeneous solution. Available immunochemical labels include free radicals, radioisotopes, fluorescent dyes, enzymes, bacteriophages or coenzymes.

[0102] In a heterogeneous assay, the reagents are typically a sample, an antibody, and a method for producing a detectable signal. Samples as described above may be used. The antibody is typically immobilized on a support, such as a bead, a plate, or a slide, and contacted with a sample suspected of containing an antigen in a liquid phase. The support is then separated from the liquid phase, and the support phase or liquid phase is examined for a detectable signal using a method for producing such a signal. The signal is associated with the presence of an analyte in the sample. Methods for producing a detectable signal include the use of radioactive labels, fluorescent labels, or enzyme labels.

[0103] For example, if the protein (or polypeptide) to be detected comprises a second binding site, an antibody that binds to this site can be conjugated to a detectable group and added to the liquid phase reaction solution prior to the separation step. The presence of the detectable group on the solid support indicates the presence of the antigen in the test sample. Examples of suitable immunoassays are radioimmunoassays, immunofluorescence methods, chemiluminescent methods, electrochemiluminescence or enzyme-linked immunosorbent assays.

[0104] Those skilled in the art will be familiar with the many specific immunoassay formats and variations thereof that can be used to practice the methods disclosed herein. See generally E. Maggio, Enzyme-lmmunoassay, (1980) (CRC Press, Inc., Boca Raton, Fla.); see also U.S. Pat. No. 4,727,022, entitled "Methods for Modulating Ligand-Receptor Interactions and their Application," by Skold et al., U.S. Pat. No. 4,659,678, entitled "Immunoassay of Antigens," by Forrest et al., U.S. Pat. No. 4,376,110, entitled "Immunometric Assays Using Monoclonal Antibodies," by David et al., U.S. Pat. No. 4,275,149, entitled "Macromolecular Environment Control in Specific Receptor Assays," by Maggio et al., U.S. Pat. No. 4,233,402, entitled "Reagents and Method Employing Channeling," and by Boguslaski et al., U.S. Pat. No. 4,233,402, entitled "Heterogenous Specific Binding Assay Employing a Coenzyme as Label” in the United States Patent No. 4,230,767.

[0105] The antibody / antigen binding moiety can be conjugated to a solid support (eg, beads, plates, slides, or wells formed from materials such as latex or polystyrene) suitable for a diagnostic assay according to known techniques, such as passive binding.

[0106] The antibody / antigen-binding portions described herein can also be conjugated to detectable groups such as radioactive labels (e.g., 35S, 125I, 131I), enzyme labels (e.g., horseradish peroxidase, alkaline phosphatase), and fluorescent labels (e.g., fluorescein) according to known techniques.

[0107] Alternative methods for detecting protein biomarkers in samples include high performance liquid chromatography (HPLC) and other high throughput techniques.

[0108] In addition, identification and quantification of one or more biomarkers can be performed using mass spectrometry. One specific example of potentially useful mass spectrometry is tandem mass spectrometry; another example is high mass accuracy / high mass resolution mass spectrometry (e.g., Orbitrap TM , Thermo Scientific).

[0109] For example, tandem mass spectrometry can be used for the quantitative analysis of peptides in biological samples due to its high sensitivity and specificity. High mass accuracy / high mass resolution mass spectrometers (such as Orbitrap TM , Thermo Scientific) can also be used for analysis.

[0110] Determine RNA transcript levels

[0111] RNA transcript expression levels can be used as an alternative measurement standard for protein levels in a sample. RNA transcript expression levels can be determined at the RNA level (i.e., mRNA or non-coding RNA (ncRNA)) (e.g., miRNA, tRNA, rRNA, snoRNA, siRNA and piRNA) or at the protein level. Measuring the gene expression of mRNA levels includes measuring the cDNA level corresponding to the mRNA.

[0112] Those skilled in the art are familiar with various techniques for determining the status of genes or proteins in tissue or cell samples, including but not limited to microarray analysis (e.g., for determining mRNA or microRNA expression, copy number, etc.), real-time PCR (RTPCR), quantitative real-time PCR (qRT-PCR, e.g., TaqMan TM ), digital PCR (dPCR), microarrays, high-throughput sequencing (also known as next-generation sequencing, such as RNA-seq), serial analysis of gene expression (SAGE), and digital gene expression (DGE), among others.

[0113] In certain embodiments, the expression level of each biomarker gene can be determined based on various features of the gene expression products, including exons, introns, protein epitopes, and protein activity.

[0114] In a specific embodiment, the RNA transcript expression level of each gene tested is quantitatively determined. Quantitative measurements typically include measuring the expression level of one or more reference or housekeeping genes in parallel to determine the standardized expression level of the test RNA transcript. This is to ensure that approximately the same amount of test sample is compared with the same amount of control sample and / or reference value or threshold.

[0115] In a specific embodiment, the determination of transcript expression levels according to the first or second aspect of the invention is performed using RT-PCR.

[0116] In a specific embodiment, RT-PCR is quantitative reverse transcription polymerase chain reaction (RT-qPCR).

[0117] Isolation, purification, primer extension and amplification of messenger RNA can be performed according to methods available in the art (see, for example, Godfrey et al., J. Molec. Diagnostics 2:84-91 (2000); Specht et al., Am. J. Pathol. 158:419-29 (2001)). RT-PCR can be performed using commercially available equipment, such as QuantStudio TM 7 Real-time PCR System (Thermo Fisher Scientific) or Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany). In a preferred embodiment, the 5' nuclease program is run on a real-time quantitative PCR device, such as QuantStudio TM 5 Real-time PCR system. The system consists of a thermal cycler, a light emitting diode (LED) and a light wavelength filter, a complementary metal oxide semiconductor (CMOS) camera and a computer. The system amplifies samples in a 96-well format on a thermal cycler. The RT-PCR can be performed in triplicate wells, equivalent to 2 ng RNA input per 10 μl reaction volume. During the amplification process, the LED-induced fluorescent signal is collected in real time, such as through a fiber optic cable of all wells, and detected on the CMOS. The system includes software for running the instrument and for analyzing the data.

[0118] In a specific embodiment, RT-qPCR is performed using primers that are capable of selectively hybridizing to target gene transcripts in the genome.

[0119] In a specific embodiment, the RNA transcript level of each gene has been normalized, for example by reference to the transcript level of at least one reference gene.

[0120] In a specific embodiment, the RT-qPCR is performed on total RNA extracted from one or more slices or sections of a cancer sample.

[0121] In a specific embodiment, RT-PCR is used to measure RNA transcript expression levels, and cycle threshold (Ct) levels are determined. Ct levels refer to the rounds or cycles of PCR that have been performed before a certain threshold of amplification products are produced. In real-time PCR assays, positive reactions are detected by the accumulation of signals (usually fluorescent signals). Ct is defined as the number of cycles required for a signal to exceed a threshold value, which is typically a background level. Sometimes Ct is referred to as Cq (quantitative cycle). Ct levels are inversely proportional to the amount of target nucleic acid in a sample.

[0122] Current PCR instruments will collect fluorescence data during each cycle and are able to calculate a Ct value.

[0123] The measured Ct level can then be normalized using the Ct of the reference gene to obtain a delta Ct (dCt). The delta Ct is a normalized Ct level corresponding to the difference between the Ct of the test gene and the Ct of the reference gene (or, if more than one reference gene is used in the experiment, the average of the reference genes). Suitably, gene expression measurements can be normalized relative to the average of one or more (e.g., 2, 3, 4, 5 or more) reference genes.

[0124] Protein levels in tumor samples can be used as a surrogate measure of RNA transcript expression levels. Protein levels in tumor samples can be determined by any technique known in the art, such as HPLC, mass spectrometry, or using antibodies specific for the selected protein (e.g., IHC, ELISA, etc.). Standardization for reference proteins can then be performed in a manner similar to RNA detection or as a ratio to a reference or by other standard methods.

[0125] Real-time PCR is compatible with both quantitative competitive PCR, where an internal competitor for each target sequence is used for normalization, and quantitative comparative PCR, which uses a normalization gene contained in the sample or a housekeeping gene for RT-PCR. For more details, see, e.g., Held et al., Genome Research 6:986-994 (1996).

[0126] Other suitable techniques that may be used include digital PCR or serial analysis of gene expression (SAGE). For more details, see, for example, Velculescu et al., Science 270:484-487 (1995); and Velculescu et al., Cell 88:243-51 (1997).

[0127] Gene expression analysis by nucleic acid sequencing

[0128] Nucleic acid sequencing technology can also be used to detect gene expression levels. The premise is that the number of times a cDNA sequence is detected in a sample is directly related to the relative expression of the mRNA corresponding to the sequence. These methods are sometimes referred to as digital gene expression (DGE) to reflect the discrete value properties of the resulting data. Early methods that applied this principle were serial analysis of gene expression (SAGE) and massively parallel signature sequencing (MPSS). See, for example, S. Brenner et al., Nature Biotechnology 18 (6): 630-634 (2000). Recently, the emergence of "next generation" sequencing technology has made DGE simpler, more efficient, and cheaper. One such example is RNA sequencing ("RNA-seq"), in which cDNA molecules are synthesized from RNA, sequenced at high throughput, and compared with a reference standard. Therefore, RNA expression can be determined by the number of comparison reads in a highly sensitive form. In addition, single transcript splicing variants can be identified and quantified, and genetic mutations or variants, such as single nucleotide polymorphisms (SNPs), can be determined.

[0129] Data analysis

[0130] In certain embodiments, the expression level of the biomarker can be compared with the expression level of the biomarker detected in the control cell, which can be obtained from non-cancerous tissue from the same or different individuals. Suitable controls include non-cancerous cells from the same tissue or pedigree. Test samples and reference samples measured at the same time or at different times can be compared. An example of the latter is to use collected expression information, such as a sequence database, which brings together information about the expression level of the biomarker.

[0131] In some embodiments, the expression of one or more reference (sometimes referred to as "housekeeping") genes or proteins is also obtained for standardizing the expression of the test gene / protein. As used herein, "reference gene or protein" refers to a gene or protein whose expression is used to calibrate or standardize the measured expression of the test protein / gene for the purpose of standardization. Standardization ensures accurate comparison of the expression of test biomarkers between different samples. To this end, reference genes / proteins known in the art can be used. Examples of biomarker expression levels of reference genes / proteins that can be standardized include, but are not limited to, GAPDH and / or actin.

[0132] The increase or decrease of biomarker expression disclosed herein can be determined based on the percentage or fold change expressed in normal cells, reference cells, or standardized relative to one or more reference or housekeeping biomarkers. Relative to the expression level in normal cells, the increase can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 120%, 140%, 160%, 180% or 200%. Alternatively, the fold increase can be 1 times, 1.5 times, 2 times, 2.5 times, 3 times, 3.5 times, 4 times, 4.5 times, 5 times, 5.5 times, 6 times, 6.5 times, 7 times, 7.5 times, 8 times, 8.5 times, 9 times, 9.5 times or 10 times the expression level in normal cells. Relative to the expression level in normal cells, the reduction can be 10%, 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, 99% or 100%. For example, a 2-fold increase or reduction is a useful measurement standard for determining whether the expression level is low or high. Suitably, according to the method of the present invention, the expression threshold level (for example, whether the patient may respond to PRMT5 inhibitor treatment) for making a prediction or judgment can be determined empirically using clinical samples.

[0133] Medical uses and treatments

[0134] According to a fourth aspect of the present invention, a PRMT5 inhibitor or a pharmaceutical composition comprising a PRMT5 inhibitor for treating a cancer patient whose cancer cells express a higher-than-normal level of an E2F1 biomarker and / or a lower-than-normal level of a pRb biomarker is provided.

[0135] In a variation of the fourth aspect of the invention, a method for treating a cancer patient whose cancer cells express higher than normal levels of an E2F1 biomarker and / or lower levels of a pRb biomarker compared to normal is provided, the method comprising administering to the patient an effective amount of a PRMT5 inhibitor or a pharmaceutical composition comprising a PRMT5 inhibitor.

[0136] In a variation of the fourth aspect of the invention, there is provided a method of treating a patient with cancer, comprising:

[0137] (i) determining the expression level of total E2F1 biomarker and / or pRb biomarker in a patient's cancer cell sample,

[0138] (ii) comparing the level determined in step (i) with the expression level in normal cells; and

[0139] (iii) if the patient's cancer cells express higher than normal levels of the E2F1 biomarker and / or reduced levels of the pRb biomarker compared to normal, administering to the patient an effective amount of a PRMT5 inhibitor or a pharmaceutical composition comprising a PRMT5 inhibitor.

[0140] In a variation of the fourth aspect of the invention, there is provided the use of a PRMT5 inhibitor in the preparation of a medicament for treating a cancer patient whose cancer cells express higher than normal levels of the E2F1 biomarker and / or reduced levels of the pRb biomarker compared to normal.

[0141] Suitably, according to the first or second aspect of the invention, a patient has been identified whose cancer cells express higher than normal levels of the E2F1 biomarker and / or reduced levels of the pRb biomarker compared to normal.

[0142] In a specific embodiment, the expression level of the E2F1 biomarker is the total E2F1 protein level.

[0143] In a specific embodiment, the expression level of the E2F1 biomarker is the level of E2F1 transcript.

[0144] In a specific embodiment, the expression level of the pRb biomarker is the pRb protein level.

[0145] In a specific embodiment, the expression level of the pRb biomarker is the RB1 transcript level.

[0146] According to a fifth aspect of the present invention, there is provided a PRMT5 inhibitor for use in treating a pRb-deficient cancer or for treating a cancer whose cells express a pRb biomarker at reduced levels compared to normal.

[0147] In a variation of the fifth aspect of the invention, a method for treating a patient having a pRb-deficient cancer or whose cancer cells express reduced levels of a pRb biomarker compared to normal is provided, the method comprising administering to the patient an effective amount of a PRMT5 inhibitor or a pharmaceutical composition comprising a PRMT5 inhibitor.

[0148] In a variation of the fifth aspect of the invention there is provided use of a PRMT5 inhibitor in the preparation of a medicament for treating a patient with pRb-deficient cancer or a patient whose cancer cells express reduced levels of a pRb biomarker compared to normal.

[0149] Suitably, according to the first or second aspect of the invention, a patient has been identified whose cancer cells express reduced levels of the pRb biomarker compared to normal.

[0150] In a specific embodiment, the expression level of the pRb biomarker is the pRb protein level.

[0151] In a specific embodiment, the expression level of the pRb biomarker is the level of RB1 protein.

[0152] In a specific embodiment, patients whose cancer cells express reduced levels of pRb biomarkers compared to normal have been identified by the cancer cells containing one or more mutations in the RB1 gene that result in reduced expression (including zero expression) of pRb.

[0153] In a specific embodiment, the one or more mutations in the RB1 gene that result in reduced (including zero) expression of pRb are selected from the group consisting of: E137X, R251X, R255X, R320X, R358X, R445X, R455X, R467X, R552X, R556X, R579X, R787X, R661W, and C712R.

[0154] In a variation of the fourth aspect of the invention, there is provided a method of treating a patient with cancer, comprising:

[0155] (i) determining whether the RB1 gene in cancer cells in a cancer cell sample from a patient comprises one or more mutations that result in reduced expression of pRb;

[0156] (ii) wherein if the RB1 gene in the cancer cell comprises one or more mutations that result in reduced expression of pRb, administering to the patient an effective amount of a PRMT5 inhibitor or a pharmaceutical composition comprising a PRMT5 inhibitor.

[0157] In a specific embodiment of the third or fourth aspect of the invention, a PRMT5 inhibitor is used in a method of treating cancer wherein the cells of the cancer express an E2F1 biomarker at a higher level than normal and a pRb biomarker at a reduced level compared to normal. As described above, a reduced level of a pRb biomarker relative to a normal level can be determined by detecting the presence of one or more mutations in the RB1 gene that result in reduced pRb expression.

[0158] In the fourth or fifth aspects of the present invention, any therapeutic drug capable of inhibiting PRMT5 can be used. In a specific embodiment, the PRMT5 inhibitor can be selected from the group consisting of: antibodies, RNA interference molecules (such as microRNA / miRNA, small interfering RNA / siRNA or short hairpin RNA / shRNA), antisense oligonucleotides (ASO) or small molecule compounds.

[0159] Suitably, the PRMT5 inhibitor for use in the third or fourth aspect of the invention is in the context of a pharmaceutical composition comprising the PRMT5 inhibitor and at least one pharmaceutically acceptable ingredient.

[0160] PRMT5 inhibitors

[0161] In the fourth or fifth aspects of the present invention, any therapeutic drug capable of inhibiting PRMT5 can be used. In a specific embodiment, the PRMT5 inhibitor can be selected from the group consisting of: antibodies, RNA interference molecules (such as microRNA / miRNA, small interfering RNA / siRNA or short hairpin RNA / shRNA), antisense oligonucleotides (ASO) or small molecule compounds.

[0162] In certain embodiments of any of the aspects disclosed herein, the PRMT5 inhibitor is a small molecule compound or a macromolecule biologic.

[0163] Suitably, the PRMT5 inhibitor is selected from the group consisting of antibodies, peptides, nucleic acids, small molecule compounds, RNA inhibitory molecules (RNAi) and antisense oligonucleotides (ASOs).

[0164] In a specific embodiment, the PRMT5 inhibitor or pharmaceutical composition thereof used according to the fourth or fifth aspect of the present invention results in a decrease in the functional activity of PRMT5 or the expression level of PRMT5.

[0165] Nucleic acid inhibitors

[0166] In a specific embodiment, the PRMT5 inhibitor used in the present invention is a nucleic acid-based therapeutic agent comprising a nucleic acid or nucleotide. For example, the nucleic acid therapeutic agent can be or comprise a dsRNA molecule, an RNAi molecule, a miRNA molecule, a ribozyme, a shRNA molecule, an antisense oligonucleotide (ASO), a guide RNA (gRNA) or a siRNA molecule.

[0167] RNAi and ASO molecules are particularly suitable for inhibiting the expression of PRMT5. The use of these methods to downregulate gene expression is now well established in the art.

[0168] In a specific embodiment, the PRMT5 inhibitor is RNAi.

[0169] In a specific embodiment, the PRMT5 inhibitor is an ASO.

[0170] The PRMT5 inhibitor for use in the present invention can also be a nucleic acid-based molecule capable of inhibiting PRMT5 mRNA. There are many different types of nucleic acid-based molecules that can inhibit the translation of mRNA and / or reduce the stability of RNA. Such RNA inhibitors are preferably RNAi molecules specific to PRMT5 mRNA; shRNA molecules specific to PRMT5 mRNA; or antisense oligonucleotides (AONs) specific to PRMT5 mRNA.

[0171] Therefore, according to another embodiment, the PRMT5 inhibitor is or comprises a nucleic acid molecule capable of inhibiting PRMT5 mRNA.

[0172] Antibody

[0173] The PRMT5 inhibitor can also be a macromolecular biological agent, such as an antibody or an antibody fragment. In a specific embodiment, the PRMT5 inhibitor is a monoclonal antibody. In a specific embodiment, the PRMT5 inhibitor is a monoclonal antibody fragment. In a specific embodiment, the PRMT5 inhibitor is a polyclonal antibody. In a specific embodiment, the PRMT5 inhibitor is an intracellular antibody.

[0174] An antibody is an immunoglobulin molecule that can specifically bind to targets, such as carbohydrates, polynucleotides, lipids, polypeptides, etc., through at least one antigen recognition site located in the variable region of the immunoglobulin molecule.

[0175] "Complete antibodies" generally refer to Y-shaped tetrameric proteins that contain two heavy (H) and two light (L) polypeptide chains, bound together by covalent disulfide bonds and non-covalent interactions. Each light chain consists of a variable domain (VL) and a constant domain (CL). Each heavy chain contains a variable domain (VH) and a constant region, which in the case of IgG, IgA and IgD antibodies contains three domains called CH1, CH2 and CH3 (IgM and IgE have a fourth domain CH4). In the IgG, IgA and IgD classes, the CH1 and CH2 domains are separated by a flexible hinge region, which is a proline and cysteine-rich fragment of variable length (about 10 to about 60 amino acids in various IgG subclasses). The variable regions in the light and heavy chains are connected to the constant regions by a "J" region of about 12 or more amino acids, and the heavy chains also have a "D" region of about 10 additional amino acids. Each type of antibody also contains interchain and intrachain disulfide bonds formed by paired cysteine ​​residues. The heavy chain variable region (YH) and light chain variable region (YL) can be further subdivided into hypervariable regions, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs). Each YH and YL contains three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of the antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.

[0176] The term "antibody" as used herein includes, for example, naturally occurring and non-naturally occurring intact antibodies, such as polyclonal, multiclonal or monoclonal antibodies, as well as chimeric antibodies, humanized and primatized antibodies, CDR-grafted antibodies, human antibodies, intracellular antibodies, multispecific antibodies, bispecific antibodies, monovalent antibodies, multivalent antibodies, anti-idiotypic antibodies and synthetic antibodies, and, unless otherwise indicated, any antigen-binding portion thereof that competes with the intact antibody for specific binding, fusion proteins comprising the antigen-binding portion, and any other modified configuration of the immunoglobulin molecule comprising an antigen recognition site.

[0177] It has been shown that the antigen binding function of an antibody can be performed by a portion of a full-length antibody. An antigen-binding portion of an antibody (also referred to as an "antigen-binding fragment") refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (eg, PRMT5) bound by the entire antibody.

[0178] Antigen binding portions include, for example, Fab, Fab', F(ab')2, F(ab') fragments, Fd, Fv, domain antibodies (dAbs, such as shark and camel antibodies), portions including complementary determining regions (CDRs), single chain variable fragment antibodies (e.g., scFv, scFvFc, and bis-scFv), minibodies, large antibodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs, and polypeptides comprising at least a portion of an immunoglobulin sufficient to confer specific antigen binding to the polypeptide. Immunoglobulins can be divided into different classes based on the amino acid sequence of the constant region of the heavy chain of the antibody. There are five major classes (i.e., isotypes) of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and some of these can be further divided into subclasses (subtypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant regions corresponding to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively. The subunit structure and three-dimensional configuration of different classes of immunoglobulins are well known. Unless the context limits otherwise, the term also includes all classes and subclasses of antibodies. The heavy chain constant regions corresponding to different classes of antibodies are usually represented by the corresponding lowercase Greek letters α, δ, ε, γ and μ, respectively. Based on the amino acid sequence of the constant region of the antibody light chain, the antibody light chain from any vertebrate species can be divided into one of two distinct types, called kappa (κ) and lambda (λ).

[0179] Although the two domains of the Fv portion, VL and VH, are encoded by different genes, they can be connected by synthetic linkers using recombinant methods to form a single protein chain in which the VL and VH regions are paired to form a monovalent molecule (called a single-chain antibody (scFv); see Bird et al., Science 242:423-426 (1988) and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988)). Such single-chain antibodies are also included in the term "antigen-binding portion" of an antibody. Other forms of single-chain antibodies, such as diabodies, are also included. Diabodies are bivalent, bispecific antibodies in which the VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow pairing between the two domains on the same chain, thereby forcing the domains to pair with the complementary domains of another chain and create two antigen-binding sites (see, e.g., Holliger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448, 1993; Poljak et al., Structure. 2:1121-1123, 1994).

[0180] The antibody can be mouse, rat, human or any other source (including chimeric or humanized antibodies). In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a human or humanized antibody. Non-human antibodies can be humanized by recombinant methods to reduce their immunogenicity in humans.

[0181] The term "monoclonal antibody" ("mAb") refers to a preparation of antibody molecules of a non-naturally occurring single molecular composition, i.e., antibody molecules of substantially identical primary sequence. MAbs are highly specific, being directed against a single antigenic site / epitope. mAbs are an example of isolated antibodies. MAbs can be produced by hybridomas, recombinant, transgenic, or other techniques known to those skilled in the art. The modifier "monoclonal" indicates that the characteristic of the antibody is obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring the antibody to be produced by any particular method. For example, the monoclonal antibodies used in accordance with the present disclosure may be prepared by the hybridoma method first described by Kohler and Milstein (Nature 256:495, 1975), or may be prepared by recombinant DNA methods, e.g., U.S. Pat. No. 4,816,567. Monoclonal antibodies may also be isolated from phage libraries produced using techniques described, for example, in McCafferty et al. (Nature 348:552-554, 1990).

[0182] "HuMAb" refers to an antibody with a variable region, wherein the framework region and CDR region are both derived from human germline immunoglobulin sequences. In addition, if the antibody contains a constant region, the constant region is also derived from human germline immunoglobulin sequences. Human antibodies may include amino acid residues that are not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or somatic mutations in vivo). However, the term "human antibody" as used herein does not include antibodies in which CDR sequences from another mammalian germline such as a mouse have been transplanted onto human framework sequences. The terms "human" antibody and "full human" antibody are used synonymously. This definition of human antibodies explicitly excludes humanized antibodies comprising non-human antigen binding residues.

[0183] "Humanized antibody" used herein refers to an antibody in which some, most or all of the amino acids outside the CDR domain of a non-human antibody are replaced by the corresponding amino acids from human immunoglobulin. In some embodiments, a humanized antibody is a human immunoglobulin (receptor antibody), wherein the residues from the receptor CDR are replaced by the residues from the CDR (donor antibody) with the desired specificity, affinity and ability from a non-human species (such as mouse, rat or rabbit). A humanized antibody may include residues that are neither present in the receptor antibody nor in the CDR or framework sequences of the input, but these residues are included to further improve and optimize antibody performance. In one embodiment of a humanized form Ab, some, most or all of the amino acids outside the CDR domain have been replaced by amino acids from human immunoglobulin, while some, most or all of the amino acids in one or more CDR regions are unchanged. A small amount of amino acid addition, deletion, insertion, substitution or modification is allowed, as long as they do not eliminate the ability of the antibody to bind to a specific antigen. "Humanized" antibodies retain antigenic specificity similar to the original antibody.

[0184] "Chimeric antibody" refers to an antibody whose variable region is from one species and whose constant region is from another species, such as an antibody whose variable region is from a mouse antibody and whose constant region is from a human antibody, or vice versa. The term also includes antibodies comprising a V region from one individual (e.g., a first mouse) of one species and a constant region from another individual (e.g., a second mouse) of the same species.

[0185] "Intracellular antibody" refers to an antibody that is designed to be expressed in cells and can be directed against specific target antigens present in various subcellular locations including cytoplasm, nucleus and endoplasmic reticulum by in-frame fusion with intracellular localization peptide sequences. It has been identified as a new class of therapeutic molecules (Chen et al., Human Gene Therapy.5(5):595–601, 1994). Although intracellular antibodies can be expressed in different forms, the most commonly used form is scFv because of their small size. Antibody fragments, usually in the form of scFv, are cloned into specific targeting vectors, allowing intracellular antibodies to be expressed in the nucleus, cytoplasm or ER. After transfection with an expression plasmid or transduction with a recombinant virus, the gene is expressed in the target cell in vivo. It has been found that common vectors, promoters and transfection systems for heterologous expression can be used to express intracellular antibodies in target cells.

[0186] Generally, the term "epitope" refers to the region of an antigen to which an antibody specifically binds, i.e., the region in physical contact with the antibody. Thus, the term "epitope" refers to a portion of a molecule that is capable of being recognized and bound by an antibody to one or more antigen-binding regions of an antibody.

[0187] "Specific binding" epitope antibody is a term well known in the art, and the method for determining such specific binding is also well known in the art. If a molecule reacts or binds to a specific cell or substance more frequently, more rapidly, for a longer duration and / or with a stronger affinity than the reaction or binding with other cells or substances, the molecule is said to exhibit "specific binding". For example, an antibody that specifically binds to a PRMT5 epitope is an antibody that binds to the epitope with stronger affinity, avidity, more easily and / or longer duration than binding to other PRMT5 epitopes or non-PRMT5 epitopes. It can also be understood by reading this definition that, for example, an antibody that specifically binds to a first target may or may not specifically or preferentially bind to a second target. Therefore, "specific binding" does not necessarily require (although it may include) exclusive binding.

[0188] For example, antibodies to PRMT5 can be prepared by any method known in the art. General techniques for producing human and mouse antibodies are known in the art and / or described herein. For example, see Harlow and Lane (1988) "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NJ.

[0189] In some embodiments, antibodies can be recombinantly prepared and expressed using any method known in the art. In some embodiments, antibodies can be prepared and selected by phage display technology. See, for example, U.S. Patent Nos. 5,565,332; 5,580,717; 5,733,743; and 6,265,50; and Winter et al., (Annu. Rev. Immunol. 12: 433-455, 1994). Alternatively, phage display technology (McCafferty et al., Nature 348: 552-553, 1990) can be used to produce human antibodies and antibody portions in vitro from immunoglobulin variable (V) domain genomic libraries of unimmunized donors.

[0190] In a specific embodiment, the antibody used in the present invention is selected from the group consisting of: a monoclonal antibody, a human antibody, a humanized antibody, a Fab antibody, a Fab antibody, a F(ab')2 antibody, a F(ab'), a Fd antibody, a Fv antibody, a dAb antibody, an intracellular antibody, a scFV antibody, and a VHH antibody.

[0191] Antibody and nucleic acid technology molecules (such as RNAi and ASO) technologies are already quite advanced, and those skilled in the art are able to produce antibodies or antibody-derived molecules or nucleic acid technology molecules that can inhibit PRMT5.

[0192] Small molecule PRMT5 inhibitor compounds

[0193] In a specific embodiment, the PRMT5 inhibitor is a small molecule compound.

[0194] "Small molecule" as used herein is an organic molecule with a mass less than about 5 kilodaltons (KDa). In some embodiments, the small molecule is less than about 3KDa, or less than about 2KDa, or less than about 1.5KDa, or less than about 1KDa. Most small molecule compounds are less than about 800 Daltons (Da). In some embodiments, the small molecule is less than about 800Da, less than about 600Da, less than about 500Da, less than about 400Da, less than about 300Da, less than about 200Da or less than about 100Da. Generally, the mass of small molecules is at least 50 Daltons. In some embodiments, small molecules are non-polymeric. In some embodiments, small molecules include multiple carbon-carbon bonds, and may include one or more heteroatoms and / or one or more functional groups important for interacting with the structure of proteins (such as hydrogen bonds), such as amino, carbonyl, hydroxyl or carboxyl, and in some embodiments, include at least two functional groups. Small molecules generally include one or more cyclic carbon or heterocyclic structures and / or aromatic or polyaromatic structures, optionally substituted by one or more of the above-mentioned functional groups.

[0195] PRMT5 inhibitor compounds with different chemophores are known. Fereira deFreitas et al. (Molecules. 24:4492, 2019) reviewed some PRMT5 inhibitors, listed their structures and outlined their mechanisms of action.

[0196] The following table lists some patent publications filed by various pharmaceutical companies, as well as other patent publications related to PRMT5 inhibitors that can be used in the present invention.

[0197]

[0198]

[0199] Compound 208 in WO 2014 / 100719 (Epizyme) is GSK3326595 (perametostat).

[0200] The compound of Example 2 in WO 2016 / 178870 (Eli Lilly) is LLY-283.

[0201] Compound 80 in WO 2017 / 032840 (Janssen Pharmaceuticals) is JNJ-64619178.

[0202] See also Fereira de Freitas et al., (Molecules. 24:4492, 2019).

[0203] Other suitable PRMT5 inhibitors include:

[0204] (1) WO 2018 / 167269 (Argonaut Therapeutics Limited) discloses a compound of formula I or a salt, solvate or hydrate thereof,

[0205]

[0206] in,

[0207] R 1 , R 3 , R 4 , R 5 and R 6 are each independently selected from hydrogen and C 1-3 alkyl;

[0208] R 2 Selected from hydrogen and R 14 ;

[0209] X is O or NR 9 , where R 9 is hydrogen or C 1-3 alkyl;

[0210] Y 1 is a group selected from one of the formulae A and B,

[0211]

[0212] wherein each R'" is independently selected from H and C 1-3 alkyl;

[0213] Q is C or N;

[0214] T is selected from fused phenyl and fused 5 or 6 membered heteroaryl, each of which is optionally substituted by one or more selected from halogen and C 1-3 The alkyl group is substituted with a substituent; and

[0215] R 7 and R 8 Together with the central nitrogen atom, it forms a 3-12 membered heterocycloalkyl ring, wherein the 3-12 membered heterocycloalkyl ring is optionally substituted by one or more R 10 substituted; and / or optionally fused to one or more C 6-12 Aryl, C 5-12 Heteroaryl, C 3-8Cycloalkyl and 3-12 membered heterocycloalkyl rings, wherein each fused C 6-12 Aryl, C 5-12 Heteroaryl, C 3-8 Cycloalkyl and 3-12 membered heterocycloalkyl rings are optionally substituted with one or more R 14 replace;

[0216] R 10 Selected from formula L 1 -L 2 -R 11 or L 2 -L 1 -R 11 A group in which L 1 Yes – [CR 12 R 13 ] n - a linker, wherein n is an integer from 0 to 3, R 12 and R 13 are each independently selected from H and C 1 To C 2 alkyl,

[0217] Where L 2 Does not exist or is selected from O, S, SO, SO 2 ,N(R'),C(O),C(O)O,[O(CH 2 ) r ] s 、[(CH 2 ) r O] s , OC(O), CH(OR'), C(O)N(R'), N(R')C(O), N(R')C(O)N(R'), SO 2 N(R') or N(R')SO 2 A linker, wherein R' and R" are each independently selected from hydrogen and C 1 To C 2 alkyl, and wherein r is 1 or 2, s is 1 to 4,

[0218] R 11 independently selected from hydrogen, CN, NO 2 , hydroxyl, =O, halogen, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Alkyl, OC 1-6 Alkyl, C 3-6 Cycloalkyl, C 6-12 Aryl, C 5-12 Heteroaryl, 3-10 membered heterocycloalkyl, –C(=O)R d 、–C(=O)OR d、–C(=O)NR e R d , –C(O)C(=O)R d ,–NR e R d ,–NR e C(=O)R d ,–NR e C(=O)OR d ,–NR e C(=O)NR e R d ,–NR e S(=O) 2 R d ,–NR e S(=O) 2 NR e R d ,–OR d ,–SR d 、–OC(=O)R d 、–OC(=O)NR e R d 、–OC(=O)OR d , –S(=O) 2 R d , –S(=O)R d 、–OS(=O)R d 、–OS(=O) 2 R d 、–OS(=O) 2 OR d 、–S(=O)NR e R d 、–OS(=O) 2 NR e R d and –S(=O) 2 NR e R d , where R 11 Independently selected from C 3-6 Cycloalkyl, C 6-12 Aryl, C 5-12 Heteroaryl and 3-10 membered heterocycloalkyl, each C 3-6 Cycloalkyl, C 6-12 Aryl, C 5-12 Heteroaryl and 3-10 membered heterocycloalkyl are optionally substituted by one or more R 14 replace;

[0219] Each R a and R b are independently selected from hydrogen and C 1-6 alkyl;

[0220] Each R d are independently selected from hydrogen, hydroxy, halogen, CN, C 1-6 Haloalkyl, 3-7 membered heterocycloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl, OC 1-6 Alkyl and C 6-11 Aryl, wherein the C 1-6 Alkyl, C 6-11 Aryl, 3-7 membered heterocycloalkyl and C 3-6 The cycloalkyl group is optionally substituted with one or more selected from hydroxy, =O, halogen, CN, COR a NR a R b , C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 6-11 Aryl, 3-7 membered heterocycloalkyl, C 1-6 Alkyl and OC 1-6 Alkyl radical substitution;

[0221] Each R e are independently selected from hydrogen, hydroxy, halogen, CN, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl and OC 1-6 Alkyl; or

[0222] R e and R d When attached to the same atom, together with the atoms to which they are attached, form a 3-7 membered heterocycloalkyl ring, optionally substituted by one or more selected from hydroxy, =O, halogen, CN, COR a NR a R b , C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 6-11 Aryl, 3-7 membered heterocycloalkyl, C 1-6 Alkyl and OC 1-6 The alkyl group is substituted with a substituent; and

[0223] R 14 Independently selected from halogen, CN, NO 2 , hydroxyl, =O, halogen, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Alkyl, OC 1-6 Alkyl, C 3-6 Cycloalkyl, C 6-12 Aryl, 5-6 membered heteroaryl, 3-7 membered heterocycloalkyl, C 1-6 Alkyl C6-12 Aryl, –C(=O)R d 、–C(=O)OR d 、–C(=O)NR e R d , –C(O)C(=O)R d ,–NR e R d ,–NR e C(=O)R d ,–NR e C(=O)OR d ,–NR e C(=O)NR e R d ,–NR e S(=O) 2 R d ,–NR e S(=O) 2 NR e R d ,–OR d ,–SR d 、–OC(=O)R d 、–OC(=O)NR e R d 、–OC(=O)OR d , –S(=O) 2 R d , –S(=O)R d 、–OS(=O)R d 、–OS(=O) 2 R d 、–OS(=O) 2 OR d 、–S(=O)NR e R d 、–OS(=O) 2 NR e R d and –S(=O)2NR e R d .

[0224] (2) WO 2018 / 167276 (Argonaut Therapeutics Limited) discloses a compound of formula I or

[0225] a salt, solvate or hydrate,

[0226]

[0227] in,

[0228] Y 1is a group selected from one of the formulae A and B,

[0229]

[0230] X is selected from O, S, CH and NR 7 ;

[0231] X 1 Selected from C and N;

[0232] Y is selected from fused aryl and fused heteroaryl, each of which is optionally substituted by one or more R 11 replace;

[0233] n is 1, L is selected from –(CH 2 ) p N(R a )C(O)–、–(CH 2 ) p C(O)N(R a )–、–(CH 2 ) p N(R a )S(O q )–、–(CH 2 ) p S(O q )N(R a )–、–(CH 2 ) p N(R b )C(O)N(R b )–、–(CH 2 ) p N(R c )C(O)O– and –(CH 2 ) p OC(O)N(R c )-;or

[0234] n is 0, L is selected from R d (R e )NC(O)–、–R d (R e )NC(O)N(R b )–, R d (R e )NC(O)O–、R d (R e )NS(O q ) and R d (R e )N–;

[0235] p is a number selected from 0, 1, 2 and 3;

[0236] q is a number selected from 1 and 2;

[0237] Z is selected from optionally one or more R 10 Substituted C 6-11 Aryl, optionally substituted with one or more R 10 Replaced (C 7-16 ) alkylaryl, optionally with one or more R 10 Substituted C 3-11 Cycloalkyl, optionally substituted by one or more R 10 Replaced (C 4-17 ) cycloalkylalkyl, optionally substituted by one or more R 10 substituted 3-15 membered heterocycloalkyl, optionally substituted by one or more R 10 substituted 4-21 membered alkylheterocycloalkyl, optionally substituted by one or more R 10 substituted 5-15 membered heteroaryl and optionally substituted by one or more R 10 Substituted 6-21 membered alkyl heteroaryl;

[0238] R 1 Selected from hydrogen, halogen, –NR e R d , OR f and optionally one or more R 9 Substituted C 1-6 alkyl;

[0239] R 2 is selected from hydrogen, halogen and optionally substituted by one or more R 9 Substituted C 1-6 alkyl;

[0240] R 3 , R 4 , R 5 and R 6 independently selected from hydrogen, halogen and optionally substituted by one or more R 9 Substituted C 1-6 alkyl;

[0241] R 7 Selected from hydrogen, hydroxyl, C 1-6 Alkyl, C 1-6 Halogenated alkyl, phenyl and C 3-6 Cycloalkyl, wherein the C 1-6 Alkyl, C 6-11 Aryl and C 3-6 The cycloalkyl group is optionally substituted with one or more selected from hydroxy, halogen, =O, CN, COR a NR a R b , C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 6-11Aryl, 3-7 membered heterocycloalkyl, C 1-6 Alkyl and OC 1-6 Substitution of alkyl groups;

[0242] Each R 9 are independently selected from hydrogen, hydroxy, halogen, CN, C 1-6 Haloalkyl, 3-7 membered heterocycloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl, OC 1-6 Alkyl and phenyl, wherein the C 1-6 Alkyl, phenyl, 3-7 membered heterocycloalkyl and C 3-6 The alkyl group is optionally substituted with one or more selected from hydroxy, =O, halogen, CN, NR a R b , COR a , C 1-6 Haloalkyl, C 3-6 Cycloalkyl, phenyl, 3-7 membered heterocycloalkyl, C 1-6 Alkyl and OC 1-6 Substitution of alkyl groups;

[0243] Each R 10 are independently selected from hydrogen, hydroxy, =O, halogen, CN, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 1-6 Alkyl, OC 1-6 Alkyl, C 3-6 Cycloalkyl, phenyl, 5-6 membered heteroaryl, 3-7 membered heterocycloalkyl, –C(=O)R d 、–C(=O)OR d 、–C(=O)NR e R d , –C(O)C(=O)R d ,–NR e R d ,–NR e C(=O)R d ,–NR e C(=O)OR d ,–NR e C(=O)NR e R d ,–NR e S(=O) 2 R d ,–NR e S(=O) 2 NR e R d ,–OR d ,–SR d 、–OC(=O)Rd 、–OC(=O)NR e R d 、–OC(=O)OR d , –S(=O) 2 R d , –S(=O)R d 、–OS(=O)R d 、–OS(=O) 2 R d 、–OS(=O) 2 OR d 、–S(=O)NR e R d 、–OS(=O) 2 NR e R d and –S(=O) 2 NR e R d , wherein the C 3-6 Cycloalkyl, C 1-6 Alkyl, phenyl, 5-6 membered heteroaryl, 3-7 membered heterocycloalkyl, optionally substituted with one or more selected from hydroxy, halogen, =O, CN, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, C 3-6 Cycloalkyl, C 1-6 Alkyl and OC 1-6 Alkyl radical substitution;

[0244] R 11 are independently selected from hydrogen, hydroxy, halogen, CN, NR a R b , C 1-6 Haloalkyl, 3-7 membered heterocycloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl, OC 1-6 Alkyl and phenyl, wherein the C 1-6 Alkyl, phenyl, 3-7 membered heterocycloalkyl and C 3-6 The cycloalkyl group is optionally substituted with one or more selected from hydroxy, =O, halogen, CN, COR a NR a R b , C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 6-11 Aryl, 3-7 membered heterocycloalkyl, C 1-6 Alkyl and OC 1-6 Substitution of alkyl groups;

[0245] Each R a , R b and R care independently selected from hydrogen and C 1-6 alkyl;

[0246] Each R d are independently selected from hydrogen, hydroxy, halogen, CN, C 1-6 Haloalkyl, 3-7 membered heterocycloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl, OC 1-6 Alkyl and C 6-11 Aryl, wherein the C 1-6 Alkyl, C 6-11 Aryl, 3-7 membered heterocycloalkyl and C 3-6 The cycloalkyl group is optionally substituted with one or more selected from hydroxy, =O, halogen, CN, COR a NR a R b , C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 6-11 Aryl, 3-7 membered heterocycloalkyl, C 1-6 Alkyl and OC 1-6 Alkyl radical substitution;

[0247] Each R e are independently selected from hydrogen, hydroxy, halogen, CN, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkyl and OC 1-6 Alkyl; or

[0248] R e and R d When attached to the same atom, together with the atoms to which they are attached, form a 3-7 membered heterocycloalkyl ring, optionally substituted by one or more selected from hydroxy, =O, halogen, CN, COR a NR a R b , C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 6-11 Aryl, 3-7 membered heterocycloalkyl, C 1-6 Alkyl and OC 1-6 The alkyl group is substituted with a substituent; and

[0249] R f independently selected from hydrogen and optionally substituted by one or more selected from hydroxy, halogen, CN, COR a NR a R b , C 1-6 Haloalkyl, C 3-6 Cycloalkyl, phenyl, 3-7 membered heterocycloalkyl and OC 1-6Alkyl substituents substituted C 1-6 alkyl.

[0250] (3) GB2108383.7 (Argonaut Therapeutics Limited) discloses a compound of formula (1) or a deuterated form, salt, solvate or hydrate thereof,

[0251]

[0252] in:

[0253] R 1A It is represented by formula (A1),

[0254]

[0255] Z is = O;

[0256] T together with the intermediate carbon and nitrogen atoms (as shown in formula (A1)) is selected from monocyclic 5 to 7 membered heterocycloalkyl, fused bicyclic 6 to 10 membered heterocycloalkyl and bridged bicyclic 6 to 9 membered heterocycloalkyl, wherein each monocyclic 5 to 7 membered heterocycloalkyl, fused bicyclic 6 to 10 membered heterocycloalkyl and bridged bicyclic 6 to 9 membered heterocycloalkyl is optionally substituted by one or more R S1 replace;

[0257] R S1 Selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 3-12 Cycloalkyl, hydroxy, halogen, CN and nitro, where C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 3-12 The cycloalkyl groups are each optionally substituted with one or more R S2 Replacement; and

[0258] R S2 Selected from hydroxy, halogen, CN and nitro.

[0259] Any of these PRMT5 compounds may be used in the present invention.

[0260] In a specific embodiment, the PRMT5 inhibitor used in the present invention is a small molecule compound selected from the group consisting of: GSK3326595 (pemrametostat), PF-6939999, JVNJ-64619178 (onametostat), LLY-283 and PRT543.

[0261] The PRMT5 inhibitor used in the fourth or fifth aspect of the present invention can be formulated into a pharmaceutical composition. The pharmaceutical composition can include at least one pharmaceutically acceptable excipient. The dosage, route of administration and actual treatment regimen can be determined by those skilled in the art.

[0262] As used herein, the term "pharmaceutically acceptable excipient" refers to one or more compatible solid or liquid fillers, diluents or encapsulating substances suitable for administration to humans. The term "excipient" means an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate application. Suitable types of excipients are salts, buffers, wetting agents, emulsifiers, preservatives, compatible carriers, diluents, carriers, vehicles, supplementary immunopotentiators such as adjuvants and cytokines, which are well known in the art and available from commercial sources for pharmaceutical formulations (see, e.g., Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Plus, 20th Ed. Mack Publishing; Kibbe et al., (2000) Handbook of Pharmaceutical Excipients, 3rd Ed., Pharmaceutical Press; and Ansel et al., (2004) Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Ed., Lippencott Williams and Wilkins). Optionally, the pharmaceutical composition comprises one or more other therapeutic agents or compounds. Suitable pharmaceutically acceptable excipients are relatively inert and may facilitate, for example, the stabilization, administration, processing or delivery of the active compound / drug into a formulation for optimal delivery to the body, preferably directly to the site of action.

[0263] The pharmaceutical composition may take the form of a solution, suspension, emulsion, tablet, pill, pellet, capsule, capsule containing a liquid, powder, sustained release formulation, suppository, emulsion, aerosol, spray, suspension, or any other form suitable for use.

[0264] When administered, the PRMT5 inhibitor is administered in the form of a pharmaceutically acceptable formulation / composition.

[0265] Administration can be enteral (eg, oral), i.e., the substance is administered through the gastrointestinal tract, or parenteral, i.e., the substance is administered by a route other than the digestive tract, such as by injection. Large biomolecules or nucleic acid molecules (eg, certain vaccines) are often administered parenterally by injection.

[0266] Pharmaceutical compositions for parenteral administration (e.g., by injection) include aqueous or non-aqueous, isotonic, pyrogen-free, sterile liquids (e.g., solutions, suspensions) in which active ingredients / drugs are dissolved, suspended, or otherwise provided (e.g., in liposomes or other microparticles). Such liquids may additionally contain one or more pharmaceutically acceptable carriers, such as antioxidants, buffers, stabilizers, preservatives, suspending agents, and solutes that make the preparation isotonic with the blood (or other relevant body fluids) of the intended patient. In a specific embodiment, the composition may be lyophilized to provide a powdered form ready for reconstruction when needed. When reconstituted by a lyophilized powder, the aqueous liquid may be further diluted before administration. For example, diluted into an infusion bag containing 0.9% sodium chloride injection, USP, or an equivalent, to achieve the desired administration dose. In a specific embodiment, such administration may be performed by intravenous infusion using an intravenous (IV) device.

[0267] Suitably, the PRMT5 inhibitor drug is formulated into a pharmaceutical composition suitable for intravenous administration to humans according to conventional procedures. Typically, the active agent for IV administration is in a solution, for example, in a sterile isotonic aqueous buffer. If necessary, the composition may also include a solubilizer. The composition for IV administration may optionally include a local anesthetic such as lidocaine to relieve pain at the injection site. In general, these ingredients are either provided separately or mixed together in a unit dose form, for example, in a sealed container such as an ampoule as a lyophilized powder or anhydrous concentrate. In the case of administering a PRMT5 inhibitor drug by infusion, an infusion bottle containing, for example, sterile pharmaceutical grade water or saline may be used for distribution. In the case of administering a PRMT5 inhibitor by injection, an ampoule of sterile water for injection or saline may be provided so that the ingredients are mixed before administration.

[0268] Compositions for oral administration can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups or elixirs, for example, prepared by conventional methods with pharmaceutically acceptable excipients, such as binders (e.g., pregelatinized corn starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silicon dioxide); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). Tablets can be coated by methods well known in the art. Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can exist as dry products for preparation with water or other suitable carriers before use. Such liquid preparations can be prepared by conventional methods with pharmaceutically acceptable additives, such as suspending agents (e.g., sorbitol syrup, cellulose derivatives, or hydrogenated edible fats); emulsifiers (e.g., lecithin or gum arabic); non-aqueous vehicles (e.g., almond oil, oily esters, ethanol, or fractionated vegetable oils); and preservatives (e.g., methyl or propyl parabens or sorbic acid). The preparations may also contain appropriate buffer salts, flavoring agents, coloring agents, and sweeteners. Oral compositions may include standard carriers such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like.

[0269] The composition used according to the present invention can be formulated in a conventional manner using one or more physiologically acceptable excipients. Therefore, the PRMT5 inhibitor drug and optionally another therapeutic or preventive drug and physiologically acceptable salts and solvates thereof can be formulated into a pharmaceutical composition for administration by inhalation or insufflation (through the mouth or nose) or oral, parenteral or mucosal (such as oral, vaginal, rectal, sublingual). In a specific embodiment, local or systemic parenteral administration is used.

[0270] The pharmaceutical compositions used in the treatment methods of the present invention are administered in an effective amount. An "effective amount" is an amount of the composition that produces the desired response alone or in combination with other doses.

[0271] Suitably, the PRMT5 inhibitor drug may be administered as a pharmaceutical composition, wherein the pharmaceutical composition comprises 0.1-1 mg, 1-10 mg, 10-50 mg, 50-100 mg, 100-500 mg or between 500 mg and 5 g of the PRMT5 inhibitor drug.

[0272] The preparation of appropriate pharmaceutical compositions and dosages for administration to patients is within the capabilities of those skilled in the art.

[0273] cancer

[0274] Various aspects of the invention using cancer cells or methods or uses for treating cancer are applicable to any cancer. Suitably, the cancer is selected from the group consisting of leukemia, lymphoma, multiple myeloma, lung cancer, liver cancer, breast cancer, head and neck cancer, neuroblastoma, thyroid cancer, skin cancer (including melanoma), oral squamous cell carcinoma, bladder cancer, testicular interstitial cell tumor, bile duct cancer (such as cholangiocarcinoma or biliary tract cancer), brain cancer, pancreatic cancer, colon cancer, colorectal cancer and gynecological cancer, including ovarian cancer, endometrial cancer, fallopian tube cancer, uterine cancer and cervical cancer, including epithelial cervical cancer. In suitable embodiments, the cancer is a leukemia and may be selected from the group consisting of: acute lymphoblastic leukemia, acute myeloid leukemia (also known as acute myeloid leukemia or acute non-lymphocytic leukemia), acute promyelocytic leukemia, acute lymphocytic leukemia, chronic myeloid leukemia (also known as chronic myeloid leukemia, chronic myelocytic leukemia or chronic granulocytic leukemia), chronic lymphocytic leukemia, monocytic leukemia, and hairy cell leukemia. In further preferred embodiments, the cancer is acute lymphoblastic leukemia. In a suitable embodiment, the cancer is a lymphoma, which may be selected from the group consisting of: Hodgkin's lymphoma; non-Hodgkin lymphoma; Burkitt's lymphoma; and small lymphocytic lymphoma.

[0275] In a specific embodiment, the cancer is selected from the group consisting of breast cancer, esophageal cancer, bladder cancer, lung cancer, hematopoietic cancer, lymphoma, medulloblastoma, rectal adenocarcinoma, colon adenocarcinoma, gastric cancer, pancreatic cancer, liver cancer, adenoid cystic carcinoma, lung adenocarcinoma, head and neck squamous cell carcinoma, brain tumor, hepatocellular carcinoma, renal cell carcinoma, melanoma, oligodendroglioma, ovarian clear cell carcinoma and ovarian serous carcinoma.

[0276] In certain embodiments, the methods and uses disclosed herein provide a precision medicine approach, such as an approach that targets a specific type of tumor, or a subgroup of patients with a specific tumor, or a tumor at a specific stage, or even an individual patient.

[0277] Suitably, the method of the first or second aspect of the invention is used to identify cancer patients who are most suitable for treatment with a PRMT5 inhibitor. Suitably, the treatment of such cancer can achieve effective treatment of cancer by preventing or treating the development of cancer, preventing or treating the progression of cancer, preventing or treating the recurrence of cancer, or preventing or treating the spread of cancer (including metastasis).

[0278] Computer-implemented method

[0279] According to a sixth aspect of the present invention, there is provided a computer-implemented method for assisting a cancer patient in selecting a treatment, comprising the following steps:

[0280] (iv) receiving a value for the level of the biomarkers (a) pRb and / or (b) total E2F1 in a biological sample comprising cancer cells from a patient;

[0281] (v) comparing the level in (i) with a reference value for each biomarker,

[0282] (vi) wherein the patient is selected for treatment with a PRMT5 inhibitor if the patient's cancer cells show decreased levels of pRb and / or increased levels of total E2F1 compared to reference values.

[0283] Suitably, the level is an expression level.

[0284] The term "computer-implemented" as used herein means that the method is performed in an automatic manner on a data processing unit, which is typically contained in a computer or similar data processing device. The data processing unit should receive values ​​of the levels of biomarkers (i.e., pRb and / or (b) total E2F1). These values ​​can be amounts, relative amounts, or any other calculated values ​​reflecting the amounts, as described in detail elsewhere herein. Therefore, it should be understood that the aforementioned methods do not require determining the amounts of biomarkers, but rather use values ​​of amounts that have been predetermined. In principle, the present invention also contemplates a computer program, a computer program product, or a computer-readable storage medium having the computer program tangibly embedded therein, wherein the computer program includes instructions that, when run on a data processing device or a computer, execute the method of the present invention as described in detail above. Specifically, the present disclosure further includes:

[0285] - a computer or a computer network comprising at least one processor, wherein the processor is adapted to perform the method according to one of the aspects described in this description,

[0286] a computer-loadable data structure which, when executed on a computer, is adapted to perform a method according to one of the aspects described in this specification,

[0287] - a computer script, wherein when the program is executed on a computer, the computer program is suitable for performing a method according to one of the aspects described in the present description,

[0288] - a computer program comprising program means for carrying out the method according to one of the aspects described in the present description when the computer program is executed on a computer or a computer network,

[0289] - a computer program comprising program means according to the preceding embodiment, wherein the program means is stored on a computer-readable storage medium,

[0290] - a storage medium, wherein a data structure is stored on the storage medium and wherein the data structure is suitable for executing a method according to one of the aspects described in the present description after being loaded into a main and / or working memory of a computer or a computer network,

[0291] - a computer program product having program code means, wherein the program code means can be stored or stored on a storage medium, and if the program code means is executed on a computer or a computer network, the program code means is for performing the method according to one of the aspects described in the present description,

[0292] - a data stream signal, typically an encrypted data stream signal, comprising data of parameters as defined elsewhere herein, and

[0293] - a data stream signal, typically an encrypted data stream signal, comprising the evaluation provided by the method of the invention.

[0294] Reagent test kit

[0295] The invention also includes kits, for example, comprising one or more means capable of quantifying the amount of pRb and / or E2F1 biomarkers in a sample.

[0296] According to a third aspect of the present invention, there is provided a kit for use in the method of the first aspect of the present invention, the kit comprising one or more reagents capable of determining the expression level of pRb and / or total E2F1. Suitably, the kit comprises an antibody or antigen binding portion thereof that specifically binds to E2F-1 protein; and / or an antibody or antigen binding portion thereof that specifically binds to pRb protein; and / or a nucleic acid oligonucleotide that can specifically bind to RB1 transcript; and / or a nucleic acid oligonucleotide that can specifically bind to E2F1 transcript.

[0297] In certain embodiments, the oligonucleotide capable of specifically binding to one of the biomarker transcripts is a primer or a probe. Optionally, the primer or probe is labeled, such as with a fluorescent or radioactive label.

[0298] Typically, the kit will contain an antibody or antigen binding portion capable of binding to a biomarker in protein form (e.g., E2F1 protein or pRb protein) and / or a primer or probe capable of binding to a biomarker in nucleic acid form (e.g., E2F1 transcript or RB1 transcript). Optionally, such an antibody or antigen binding portion, primer or probe may be labeled, such as a fluorescent label. The kit may also include instructions for use and may also include additional elements required to implement the methods described in the kit instructions. The kit may also include information about interpreting data and making decisions, such as a threshold level for interpreting whether the level of a biomarker indicates that the patient may respond favorably to a PRMT5 inhibitor.

[0299] The kit comprises an antibody or epitope-binding fragment thereof as described herein. The kit may also include a tool for obtaining a biological sample, such as a spatula or a dipstick or a container for receiving a sample. The kit may also include one or more assay components for detecting the amount of total E2F-1 or pRb protein. Preferably, the assay comprises an immunoassay, such as an ELISA. The kit may also include one or more assay components for detecting E2F-1 or RB1 transcripts. Preferably, the assay is RT-PCR.

[0300] In certain embodiments, the kit further comprises a positive control and / or a negative control. These process controls serve as quality control to ensure valid assay results.

[0301] The presence and / or amount of total E2F-1 or pRB protein in a sample can be determined by standard immunochemical techniques well known to the skilled artisan (e.g., immunohistochemistry, radioimmunoassay, ELISA, Western blot, fluorescence assay, LANCE, FRET, etc.). The method can preferably be performed as a high throughput screen.

[0302] The presence and / or amount of E2F-1 or RB1 transcripts in a sample can be determined by standard nucleic acid quantification techniques well known to the skilled person (eg RT-PCR, qPCR).

[0303] An increase in total E2F-1 protein or E2F-1 encoding transcripts in a patient's cancer cell sample compared to a reference value (eg, the level in a normal cell sample or a normal reference value) indicates that the patient is suitable for treatment with a PRMT-5 inhibitor.

[0304] A decrease in the amount of pRb protein or RB1 transcript in a patient's cancer cell sample compared to a reference value (eg, a normal cell sample or a normal reference value) indicates that the patient is suitable for treatment with a PRMT-5 inhibitor.

[0305] Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned herein are incorporated herein by reference. Aspects and embodiments of the present invention will now be discussed with reference to the following examples and drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0306] Figure 1 .

[0307] PRMT5 inhibition mediates cancer cell death, an effect that is E2F1-dependent. U2OS cells were transfected with PRMT5 (P5), E2F-1 (E2F1), or control (NC) or siRNA as indicated, and colony growth was measured 10 days after staining with crystal violet. (a) Levels of E2F1 and PRMT5 in siRNA-treated cells are shown by Western blotting (b).

[0308] Figure 2 .

[0309] Cells deficient in E2F1 are less sensitive to PRMT5 inhibition.

[0310] (a) Cell viability assay in T-47D cell line (breast cancer), (b) Cell viability assay in HCT116 cell line (colorectal cancer).

[0311] Figure 3 .

[0312] Cells lacking the pRb gene are more sensitive to PRMT5 inhibition.

[0313] (a) Cell viability assay in T-47D cell line (breast cancer), (b) Cell viability assay in U2OS cell line (bone cancer).

[0314] Figure 4 .

[0315] Cells lacking E2F1 are less sensitive to the PRMT5 inhibitor GSK3326595.

[0316] (a) Cell viability assay in HCT116 cell line (colorectal cancer), (b) Cell viability assay in T-47D cell line (breast cancer).

[0317] Figure 5 .

[0318] Cells lacking the E2F1 gene are less sensitive to the PRMT5 inhibitor PF06939999.

[0319] (a) Cell viability assay in HCT116 cell line (colorectal cancer), (b) Cell viability assay in T-47D cell line (breast cancer).

[0320] Figure 6 .

[0321] Cell viability assay in HCT116 cell line (colorectal cancer).

[0322] Cells lacking E2F1 gene are less sensitive to PRMT5 inhibitor JNJ64619178.

[0323] Figure 7 .

[0324] Cell viability assay in HCT116 cell line (colorectal cancer).

[0325] E2F1-deficient cells were less sensitive to the PRMT5 inhibitor LLY283.

[0326] Figure 8 .

[0327] Cell viability assay in T-47D cell line (breast cancer). pRb-deficient cells are more sensitive to the PRMT5 inhibitor GSK3326595.

[0328] Fig. 9 .

[0329] Cell viability assay in T-47D cell line (breast cancer). Cells with pRb gene deletion are more sensitive to the PRMT5 inhibitor PF06939999.

[0330] sequence:

[0331] SEQ ID NO:1

[0332] Gene name: RB1 (RB transcriptional corepressor 1)

[0333] Gene ID: 5925

[0334] Protein ID: NP_000312.2

[0335] CCDS:CCDS31973.1

[0336] RB1 nucleotide sequence (2787 nt):

[0337]

[0338] SEQ ID NO:2

[0339] Translation (928aa):

[0340] MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTELQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSSISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYKTAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFMNSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKSNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVKDIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDNIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEGNLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNHTAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYLRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLKFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLSPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQKLAEMTSTRTRMQKQKMNDSMDTSNKEEK

[0341] SEQ ID NO:3

[0342] Gene name: E2F1 (E2F transcription factor 1)

[0343] Gene ID: 1869

[0344] Protein ID: NP_005216-1

[0345] CCDS:CCDS13224.1

[0346] E2F1 nucleotide sequence (1314 nt):

[0347]

[0348] SEQ ID NO:4

[0349] Translation (437aa):

[0350] MALAGAPAGGPCAPALEALLGAGALRLLDSSQIVIISAAQDASAPPAPTGPAAPAAGPCDPDLLLFATPQAPRPTPSAPRPALGRPPVKRRLDLETDHQYLAESSGPAR GRGRHPGKGVKSPGEKSRYETSLNLTTKRFLELLSHSADGVVDLNWAAEVLKVQKRRIYDITNVLEGIQLIAKKSKNHIQWLGSHTTVGVGGRLEGLTQDLRQLQESEQ Question

[0351] SEQ ID NO:5

[0352] PRMT5 siRNA sequences

[0353] CCG CUAUUG CAC CUU GGA A

[0354] SEQ ID NO:6

[0355] E2F-1 siRNA sequence:

[0356] AAC UCC UCG CAG AUC GUC AUC

[0357] Example

[0358] Example 1

[0359] The role of PRMT5 and E2F-1 in growth control was assessed in U2OS cells. When cell growth was analyzed, the inhibitory effect of PRMT5 was evident when cell growth was measured in the context of a colony formation assay, where PRMT5 siRNA caused a significant decrease in growth after 10 days, which was rescued after co-depletion of E2F-1 ( Figure 1 a) Protein levels of PRMT5 and E2F1 are shown in Figure 1 b. Silencing PRMT5 activity with gene-specific siRNA resulted in cell death by apoptosis. Furthermore, this cell death required E2F1 activity, as co-silencing of E2F1 and PRMT5 rescued cell death and allowed cells to continue growing ( Figure 1 a).

[0360] Example 2

[0361] Tumor cells lacking the E2F1 gene were less sensitive to AT101-mediated PRMT5 inhibition. In colorectal and breast cancer cell lines in which E2F1 was deleted using CRISPR technology, E2F1 depletion desensitized the cells to PRMT5 inhibition ( Figure 2 (a) and (b)), indicating that E2F1 is a positive marker in response to PRMT5 inhibition.

[0362] Example 3

[0363] Tumor cells lacking the gene for the tumor suppressor protein pRb are more sensitive to AT101-mediated PRMT5 inhibition. In breast cancer and bone cancer cell lines in which pRb was deleted using CRISPR technology, pRb depletion sensitized cells to PRMT5 inhibition ( Figure 3 (a) and (b)), indicating that pRb is a negative marker in response to PRMT5 inhibition.

[0364] Example 4

[0365] Tumor cells lacking the E2F1 gene are less sensitive to GSK3326595-mediated PRMT5 inhibition. In colorectal and breast cancer cell lines in which E2F1 was deleted using CRISPR technology, E2F1 depletion desensitized the cells to GSK3326595-mediated PRMT5 inhibition ( Figure 4 (a) and (b)), indicating that E2F1 is a positive marker in response to GSK332659-mediated PRMT5 inhibition.

[0366] Example 5

[0367] Tumor cells lacking the E2F1 gene are less sensitive to PF06939999-mediated PRMT5 inhibition. In colorectal and breast cancer cell lines in which E2F1 was deleted using CRISPR technology, E2F1 depletion desensitized the cells to PF06939999 PRMT5 inhibition ( Figure 5 (a) and (b)), indicating that E2F1 is a positive marker in response to PF06939999-mediated PRMT5 inhibition.

[0368] Example 6

[0369] Tumor cells lacking the E2F1 gene are less sensitive to JNJ64619178-mediated PRMT5 inhibition. In the breast cancer cell line T-47D, in which E2F1 was deleted using CRISPR technology, E2F1 depletion desensitized the cells to JNJ64619178 PRMT5 inhibition ( Figure 6 ), indicating that E2F1 is a positive marker in response to JNJ64619178-mediated PRMT5 inhibition.

[0370] Example 7

[0371] Tumor cells lacking the E2F1 gene were less sensitive to LLY-283-mediated PRMT5 inhibition. In the breast cancer cell line T-47D, in which E2F1 was deleted using CRISPR technology, E2F1 depletion desensitized the cells to LLY-283 PRMT5 inhibition ( Figure 7 ), indicating that E2F1 is a positive marker in response to LLY-283-mediated PRMT5 inhibition.

[0372] Example 8

[0373] Tumor cells lacking the gene for the tumor suppressor protein pRb are more sensitive to GSK3326595-mediated PRMT5 inhibition. In breast cancer cell lines in which pRb was deleted using CRISPR technology, pRb depletion sensitized cells to GSK3326595 PRMT5 inhibition ( Figure 8 ), indicating that pRb is a negative marker in response to GSK3326595-mediated PRMT5 inhibition.

[0374] Example 9

[0375] Tumor cells lacking the gene for the tumor suppressor protein pRb are more sensitive to PF06939999-mediated PRMT5 inhibition. In breast cancer cell lines in which pRb was deleted using CRISPR technology, pRb depletion sensitized cells to PF06939999 PRMT5 inhibition ( Fig. 9 ), indicating that pRb is a negative marker in response to PF06939999-mediated PRMT5 inhibition.

[0376] Materials and Methods

[0377] MTT assay

[0378] T-47D cells were maintained in growth medium (RPMI 1640 supplemented with 10% v / v heat-inactivated fetal bovine serum) and cultured at 37°C, 5% CO 2U2OS, MCF7, and HCT116 cells were maintained in growth medium (DMEM supplemented with 10% v / v heat-inactivated fetal bovine serum) and cultured at 37°C, 5% CO 2 Under the assay conditions, the cells were cultured at 37°C and 5% CO 2 The cells were incubated in assay medium (RPMI 1640 or DMSO supplemented with 10% v / v heat-inactivated fetal bovine serum and 100 units / mL penicillin-streptomycin). To evaluate the effects of compounds on the proliferation of cancer cell lines, exponentially growing cells were seeded into 96-well plates overnight at a density of 1,000 cells / well in a final volume of 100 μl of cell growth medium. The next day, compounds (T-992, GSK3326595, LLY-283, PF-06939999, and JNJ64619178) were added to the cells (four replicates of ten-point 5-fold serial dilutions in DMSO), starting at 100 μM. After the addition of the compounds, the assay plates were incubated at 37°C, 5% CO 2 , incubated at 90% relative humidity for 8 days. NAD(P)H-dependent cellular oxidoreductase activity was measured by adding 100 μl of thiazolyl blue tetrazolium bromide (MTT; Sigma-Aldrich) to the wells at a final concentration of 5 μM and incubated at 37°C for 2 h. Next, the culture medium was discarded from the wells and the formazan crystals were dissolved in 100 μl of DMSO by shaking for 15 min. The absorbance was read at a wavelength of 584 nM on an Omega FLUOstar microplate reader (BMG Labtech Ltd, Ortenberg, Germany). MAR data analysis software (BBMG Labtech Ltd, Ortenberg, Germany) was used to analyze the data and determine the IC50 value. The 4-parameter fit of the standardized dose-response curve was used to determine the compound concentration that inhibited cell viability by 50%.

[0379] Western blotting

[0380] Cells were harvested, washed in PBS, and resuspended in lysis buffer [50 mM Tris pH 7.4, 5 mM EDTA, 0.5% Igepal CA-630 (Sigma, Gillingham, UK), 50 mM NaF, 1 mM DTT, 0.2 mM Na 3 VO 4, 120 mM NaCl, protease inhibitor cocktail]. Total protein concentration was determined by Bradford assay (Bio-Rad). Whole cell lysates were prepared, separated by 4-20% SDS-PAGE (Bio-rad), and transferred to PVDF membranes (GE Healthcare, Piscataway, NJ). The membranes were blocked with 5% milk in PBS containing 0.2% Tween 20 for 1 h at room temperature. Primary antibodies for actin (Sigma, A2228), E2F1 (CST#3742), and Rb (#9309) were diluted in 5% milk at a ratio of 1:1000 and incubated overnight at 4°C. The membranes were washed with PBS-T, incubated with HRP-conjugated secondary antibodies (CST) diluted in PBS-T containing 5% milk for 1 hour at room temperature, washed, and developed using SuperSignal West Dura chemiluminescent substrate (Thermo Scientific).

[0381] Colony formation assay

[0382] U2OS cells were seeded in 6-well plates at a density of 1000 cells / well and transfected with siRNA as described in the following sections. U2OS cells were allowed to establish colonies for 10 days before the end of the experiment. The culture medium was gently aspirated to avoid physical damage to the cells and the plates were briefly rinsed with PBS. Crystal violet (Sigma-Aldrich) stain (0.5%) was applied to the cells for 2 minutes, followed by rinsing with autoclaved deionized water and air drying. Using a Gelcounter TM A colony counter (Oxford Optronics) scanned the plates and measured and counted the colonies.

[0383] siRNA transfection

[0384] Oligofectamine reagent (Invitrogen) and siRNA complexes (non-targeting, E2F1 and PRMT5) were used to Reduced serum medium Incubate at room temperature for 5 minutes. Combine the two mixtures and incubate for another 20 minutes. Add the siRNA transfection mixture to U2OS cells in a dropwise manner. Commercial non-targeting siRNA controls are from Dharmacon. PRMT5 siRNA sequence: 5'-CCG CUA UUG CAC CUU GGA A-3' (SEQ ID NO:5), E2F-1 siRNA sequence: 5'-AAC UCC UCG CAG AUC GUC AUC-3' (SEQ ID NO:6) [sense strand shown]. In experiments involving more than one siRNA treatment, non-targeting siRNA was included to ensure equal amounts of transfected siRNA in all samples.

[0385] CRISPR-Cas9 gene disruption

[0386] pSpCas9(BB)-2A-Puro (Addgene plasmid ID: 48139) was used to generate E2F1 and pRb knockout cell lines using CRISPR-Cas9 technology. Cell lines were generated as described in (Ran et al., 2013).

[0387] References

[0388] Bandara, LR, & La Thangue, NB (1991). Adenovirus E1a prevents theretinoblastoma gene product from complexing with a cellular transcription factor. Nature, 351(6326), 494–497. https: / / doi.org / 10.1038 / 351494a0

[0389] Barczak, W., Jin, L., Carr, SM, Munro, S., Ward, S., Kanapin, A., Samsonova, A., & La Thangue, NB (2020). PRMT5 promotes cancer cell migration and invasion through the E2F pathway. Cell Death & Disease, 11(7), 572.

[0390] https: / / doi.org / 10.1038 / s41419-020-02771-9

[0391] Bedford,M.T.,&Clarke,S.G.(2009).Protein arginine methylation inmammals:Who,what,and why.Molecular Cell,33(1),1–13.

[0392] https: / / doi.org / 10.1016 / j.molcel.2008.12.013

[0393] Benedict,W.F.,Lerner,S.P.,Zhou,J.,Shen,X.,Tokunaga,H.,&Czerniak,B.(1999).Level of retinoblastoma protein expression correlates with p16(MTS-1 / INK4A / CDKN2)status in bladder cancer.Oncogene,18(5),1197–1203.

[0394] https: / / doi.org / 10.1038 / sj.onc.1202452

[0395] Bhateja,P.,Chiu,M.,Wildey,G.,Lipka,M.B.,Fu,P.,Yang,M.C.L.,Ardeshir-Larijani,F.,Sharma,N.,&Dowlati,A.(2019).Retinoblastoma mutation predicts pooroutcomes in advanced non small cell lung cancer.Cancer Medicine,8(4),1459–1466.https: / / doi.org / 10.1002 / cam4.2023

[0396] Cho , E.-C. , Zheng , S. , Munro , S. , Liu , G. , Carr , SM , Moehlenbrink , J. , Lu , Y.-C. , Stimson , L. , Khan , O.,Konietzny,R.,McGouran,J.,Coutts,AS,Kessler,B.,Kerr,DJ,&Thangue,NBL(2012).Arginine Methylation controls growth regulation byE2F-1.The EMBO Journal,31(7),1785–1797.

[0397] Methyltransferase Inhibitors:Competingwith,or Exploiting the Bound Cofactor.Molecules 24,4492.

[0398] Derenzini, M., Donati, G., Mazzini, G., Montanaro, L., Vici, M., Ceccarelli, C., Santini, D., Taffurelli, M., &Treré, D. (2008). Research:An Official Journal of the American Association for Cancer Research,14(7),2199–2209

[0399] Dick,F.A.,&Rubin,S.M.(2013).Molecular mechanisms underlying RBprotein function.Nature Reviews.Molecular Cell Biology,14(5),297–306.

[0400] https: / / doi.org / 10.1038 / nrm3567

[0401] Ertel,A.,Dean,J.L.,Rui,H.,Liu,C.,Witkiewicz,A.K.,Knudsen,K.E.,&Knudsen,E.S.(2010).RB-pathway disruption in breast cancer.Cell Cycle,9(20),4153–4163.https: / / doi.org / 10.4161 / cc.9.20.13454

[0402] Field,S.J.,Tsai,F.Y.,Kuo,F.,Zubiaga,A.M.,Kaelin,W.G.,Livingston,D.M.,Orkin,S.H.,&Greenberg,M.E.(1996).E2F-1 functions in mice to promote apoptosisand suppress proliferation.Cell,85(4),549–561.

[0403] https: / / doi.org / 10.1016 / s0092-8674(00)81255-6

[0404] Frolov,M.V.,&Dyson,N.J.(2004).Molecular mechanisms of E2F-dependentactivation and pRB-mediated repression.Journal of Cell Science,117(Pt 11),2173–2181.https: / / doi.org / 10.1242 / jcs.01227

[0405] Hanahan,D.,&Weinberg,R.A.(2000).The hallmarks of cancer.Cell,100(1),57–70.https: / / doi.org / 10.1016 / s0092-8674(00)81683-9

[0406] Iaquinta,P.J.,&Lees,J.A.(2007).Life and death decisions by the E2Ftranscription factors.Current Opinion in Cell Biology,19(6),649–657.

[0407] https: / / doi.org / 10.1016 / j.ceb.2007.10.006

[0408] Jackson,S.P.,&Bartek,J.(2009).The DNA-damage response in humanbiology and disease.Nature,461(7267),1071–1078.https: / / doi.org / 10.1038 / nature08467

[0409] Jarrold,J.,&Davies,C.C.(2019).PRMTs and Arginine Methylation:Cancer’sBest-Kept Secret?Trends in Molecular Medicine,25(11),993–1009.

[0410] https: / / doi.org / 10.1016 / j.molmed.2019.05.007

[0411] Kim,H.,&Ronai,Z.A.(2020).PRMT5 function and targeting in cancer.CellStress,4(8),199–215.https: / / doi.org / 10.15698 / cst2020.08.228

[0412] Knudsen, ES, Nambiar, R., Rosario, SR, Smiraglia, DJ, Goodrich, DW, & Witkiewicz, AK(2020).Pan-cancer molecular analysis of the RB tumor suppressor pathway.Communications Biology,3(1),1–12.https: / / doi.org / 10.1038 / s42003-020-0873-9

[0413] Lacombe , C. , De Rycke , O. , Couvelard , A. , Turpin , A. , Cazes , A. , Hentic , O. , Gounant , V. , Zalcman , G. , Ruszniewski , P. , Cross , J. , & de Mestier , L. (2021).

[0414] Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patientswith Grade 3 Neuroendocrine Neoplasms.Cancers,13(4),643.

[0415] https: / / doi.org / 10.3390 / cancers13040643

[0416] Pediconi, N., Ianari, A., Costanzo, A., Belloni, L., Gallo, R., Cimino, L., Porcellini, A., Screpanti, I., Balsano, C., Alesse, E., Gulino, A., &Levrero, M. (2003).

[0417] Differential regulation of E2F1 apoptotic target genes in response toDNA damage.Nature Cell Biology,5(6),552–558

[0418] Polager,S.,&Ginsberg,D.(2008).E2F-at the crossroads of life anddeath.Trends in Cell Biology,18(11),528–535.https: / / doi.org / 10.1016 / j.tcb.2008.08.003

[0419] Ran,F.A.,Hsu,P.D.,Wright,J.,Agarwala,V.,Scott,D.A.,&Zhang,F.(2013).

[0420] Genome engineering using the CRISPR-Cas9 system.Nature Protocols,8(11),2281–2308.https: / / doi.org / 10.1038 / nprot.2013.143

[0421] Shailesh,H.,Zakaria,Z.Z.,Baiocchi,R.,&Sif,S.(2018).Protein argininemethyltransferase 5(PRMT5)dysregulation in cancer.Oncotarget,9(94),36705–36718.https: / / doi.org / 10.18632 / oncotarget.26404

[0422] Stevens,C.,&La Thangue,N.B.(2003).E2F and cell cycle control:Adouble-edged sword.Archives of Biochemistry and Biophysics,412(2),157–169.

[0423] https: / / doi.org / 10.1016 / s0003-9861(03)00054-7

[0424] Stevens,C.,Smith,L.,&La Thangue,N.B.(2003).Chk2 activates E2F-1 inresponse to DNA damage.Nature Cell Biology,5(5),401–409.

[0425] https: / / doi.org / 10.1038 / ncb974

[0426] Tsai,K.Y.,Hu,Y.,Macleod,K.F.,Crowley,D.,Yamasaki,L.,&Jacks,T.(1998).

[0427] Mutation of E2f-1 suppresses apoptosis and inappropriate S phaseentry and extends survival of Rb-deficient mouse embryos.Molecular Cell,2(3),293–304.

[0428] https: / / doi.org / 10.1016 / s1097-2765(00)80274-9

[0429] van den Heuvel,S.,&Dyson,N.J.(2008).Conserved functions of the pRBand E2F families.Nature Reviews.Molecular Cell Biology,9(9),713–724.

[0430] https: / / doi.org / 10.1038 / nrm2469

[0431] Xing,E.P.,Yang,G.Y.,Wang,L.D.,Shi,S.T.,&Yang,C.S.(1999).Loss ofheterozygosity of the Rb gene correlates with pRb protein expression andassociates with p53 alteration in human esophageal cancer.Clinical CancerResearch:An Official Journal of the American Association for Cancer Research,5(5),1231–1240.

[0432] Zamanian,M.,&La Thangue,N.B.(1992).Adenovirus E1a prevents theretinoblastoma gene product from repressing the activity of a cellulartranscription factor.The EMBO Journal,11(7),2603–2610.

[0433] Zheng,S.,Moehlenbrink,J.,Lu,Y.-C.,Zalmas,L.-P.,Sagum,C.A.,Carr,S.,McGouran,J.F.,Alexander,L.,Fedorov,O.,Munro,S.,Kessler,B.,Bedford,M.T.,Yu,Q.,&La Thangue,N.B.(2013).Arginine methylation-dependent reader-writerinterplay governs growth control by E2F-1.Molecular Cell,52(1),37–51.

[0434] https: / / doi.org / 10.1016 / j.molcel.2013.08.03

[0435] Yu,Q.,&La Thangue,N.B.(2013).Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1.Molecular Cell,52(1),37–51.

[0436] https: / / doi.org / 10.1016 / j.molcel.2013.08.039

Claims

1. A method for selecting a treatment for a cancer patient, comprising: (i) Determining the biomarker (a) pRb in a biological sample containing cancer cells from the patient and / or (b) expression level of total E2F1; (ii) comparing the expression levels in (i) with the reference values ​​for each biomarker, (iii) wherein said patient is selected for treatment with a PRMT5 inhibitor if said patient's cancer cells show decreased pRb expression and / or increased total E2F1 expression compared to said reference value.

2. The method of claim 1, wherein the expression level is protein or nucleic acid expression.

3. The method according to claim 1 or 2, wherein the determination is based on the expression level of total E2F1 protein. The method according to claim 1 , wherein the determination is based on the expression level of the pRb protein.

5. The method of claim 1 or 2, wherein the determination is based on the expression levels of pRb and total E2F1.

6. A method according to any one of the preceding claims, wherein the level of protein is detected using an antibody that binds to the protein. The method of claim 6 , wherein the antibody is a monoclonal antibody.

8. The method of any one of claims 1, 2, 4 and 5, wherein the reduced pRb expression level is determined indirectly by identifying RB1 mutations indicative of reduced or null expression in cancer cells.

9. A method for selecting a treatment for a cancer patient, comprising determining whether the PRB1 gene in the cancer cell contains one or more mutations that result in reduced pRb expression, including zero expression, wherein if the cancer cell contains one or more mutations in the PRB1 gene that result in reduced pRb expression, the patient is selected for treatment with a PRMT5 inhibitor.

10. The method of any one of the preceding claims, wherein the cancer is selected from the group consisting of leukemia, lymphoma, multiple myeloma, lung cancer, liver cancer, breast cancer, head and neck cancer, neuroblastoma, thyroid cancer, skin cancer (including melanoma), oral squamous cell carcinoma, bladder cancer, testicular Leydig cell tumor, bile duct cancer such as cholangiocarcinoma or biliary tract cancer, brain cancer, pancreatic cancer, colon cancer, colorectal cancer, and gynecological cancers, including ovarian cancer, endometrial cancer, fallopian tube cancer, uterine cancer, and cervical cancer, including epithelial cervical cancer. In suitable embodiments, the cancer is a leukemia and may be selected from the group consisting of: acute lymphoblastic leukemia, acute myeloid leukemia (also known as acute myeloid leukemia or acute non-lymphocytic leukemia), acute promyelocytic leukemia, acute lymphocytic leukemia, chronic myeloid leukemia (also known as chronic myeloid leukemia, chronic myeloid leukemia or chronic granulocytic leukemia), chronic lymphocytic leukemia, monocytic leukemia, and hairy cell leukemia. In further preferred embodiments, the cancer is acute lymphoblastic leukemia. In a suitable embodiment, the cancer is a lymphoma, which may be selected from the group consisting of: Hodgkin's lymphoma; non-Hodgkin's lymphoma; Burkitt's lymphoma; and small lymphocytic lymphoma.

11. A kit for use in a method of identifying a cancer that may be susceptible to treatment by inhibiting PRMT5, wherein the kit comprises an antibody or antigen-binding portion thereof that specifically binds to E2F-1 protein; and / or an antibody or antigen-binding portion thereof that specifically binds to pRb protein; and / or a nucleic acid oligonucleotide that specifically binds to RB1 transcript; and / or a nucleic acid oligonucleotide that specifically binds to E2F1 transcript.

12. The kit according to claim 11, wherein the kit further comprises assay reagents and / or instructions for use for detecting antibody target binding or nucleic acid oligonucleotide target binding.

13. A PRMT5 inhibitor for use in treating cancer, wherein cells of said cancer express higher than normal levels of total E2F1 protein and / or reduced levels of pRb protein compared to normal. The PRMT5 inhibitor of claim 13 , wherein the cancer cells express higher than normal levels of total E2F1 protein. The PRMT5 inhibitor according to claim 13 or 14, wherein the cancer cells express a reduced level of pRb protein compared to normal cells. The PRMT5 inhibitor according to any one of claims 13 to 15, wherein the cancer cells express higher-than-normal levels of total E2F1 protein and reduced-level pRb protein compared to normal.

17. A PRMT5 inhibitor for use in treating a pRb-deficient cancer or a cancer whose cells express reduced levels of pRb protein compared to normal cells. 18 . The PRMT5 inhibitor according to claim 13 , which is selected from the group consisting of an antibody, an RNA interference molecule, an antisense oligonucleotide or a small molecule compound.

19. The PRMT5 inhibitor according to claim 14, wherein the small molecule compound PRMT5 inhibitor is selected from the group consisting of: GSK3326595 (pemrametostat), PF-6939999, JNJ-64619178 (onametostat) and LLY-283.

20. The PRMT5 inhibitor of any one of claims 13 to 19, wherein the cancer is selected from the group consisting of leukemia, lymphoma, multiple myeloma, lung cancer, liver cancer, breast cancer, head and neck cancer, neuroblastoma, thyroid cancer, skin cancer (including melanoma), oral squamous cell carcinoma, bladder cancer, testicular Leydig cell tumor, bile duct cancer such as cholangiocarcinoma or biliary tract cancer, brain cancer, pancreatic cancer, colon cancer, colorectal cancer, and gynecological cancers, including ovarian cancer, endometrial cancer, fallopian tube cancer, uterine cancer, and cervical cancer, including epithelial cervical cancer. In suitable embodiments, the cancer is a leukemia and may be selected from the group consisting of: acute lymphoblastic leukemia, acute myeloid leukemia (also known as acute myeloid leukemia or acute non-lymphocytic leukemia), acute promyelocytic leukemia, acute lymphocytic leukemia, chronic myeloid leukemia (also known as chronic myeloid leukemia, chronic myeloid leukemia or chronic granulocytic leukemia), chronic lymphocytic leukemia, monocytic leukemia, and hairy cell leukemia. In further preferred embodiments, the cancer is acute lymphoblastic leukemia. In a suitable embodiment, the cancer is a lymphoma, which may be selected from the group consisting of: Hodgkin's lymphoma; non-Hodgkin's lymphoma; Burkitt's lymphoma; and small lymphocytic lymphoma.

21. The PRMT5 inhibitor of claim 17, wherein the cancer is selected from the group consisting of breast cancer, esophageal cancer, bladder cancer, lung cancer, hematopoietic cancer, lymphoma, medulloblastoma, rectal adenocarcinoma, colon adenocarcinoma, gastric cancer, pancreatic cancer, liver cancer, adenoid cystic carcinoma, lung adenocarcinoma, head and neck squamous cell carcinoma, brain tumor, hepatocellular carcinoma, renal cell carcinoma, melanoma, oligodendroglioma, ovarian clear cell carcinoma, and ovarian serous carcinoma.